1
|
Hudson EM, Noutch S, Webster J, Brown SR, Boele FW, Al-Salihi O, Baines H, Bulbeck H, Currie S, Fernandez S, Hughes J, Lilley J, Smith A, Parbutt C, Slevin F, Short S, Sebag-Montefiore D, Murray L. Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial. BMJ Open 2024; 14:e078926. [PMID: 38458809 DOI: 10.1136/bmjopen-2023-078926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/10/2024] Open
Abstract
INTRODUCTION Glioblastoma (GBM) is the most common adult primary malignant brain tumour. The condition is incurable and, despite aggressive treatment at first presentation, almost all tumours recur after a median of 7 months. The aim of treatment at recurrence is to prolong survival and maintain health-related quality of life (HRQoL). Chemotherapy is typically employed for recurrent GBM, often using nitrosourea-based regimens. However, efficacy is limited, with reported median survivals between 5 and 9 months from recurrence. Although less commonly used in the UK, there is growing evidence that re-irradiation may produce survival outcomes at least similar to nitrosourea-based chemotherapy. However, there remains uncertainty as to the optimum approach and there is a paucity of available data, especially with regards to HRQoL. Brain Re-Irradiation Or Chemotherapy (BRIOChe) aims to assess re-irradiation, as an acceptable treatment option for recurrent IDH-wild-type GBM. METHODS AND ANALYSIS BRIOChe is a phase II, multi-centre, open-label, randomised trial in patients with recurrent GBM. The trial uses Sargent's three-outcome design and will recruit approximately 55 participants from 10 to 15 UK radiotherapy sites, allocated (2:1) to receive re-irradiation (35 Gy in 10 daily fractions) or nitrosourea-based chemotherapy (up to six, 6-weekly cycles). The primary endpoint is overall survival rate for re-irradiation patients at 9 months. There will be no formal statistical comparison between treatment arms for the decision-making primary analysis. The chemotherapy arm will be used for calibration purposes, to collect concurrent data to aid interpretation of results. Secondary outcomes include HRQoL, dexamethasone requirement, anti-epileptic drug requirement, radiological response, treatment compliance, acute and late toxicities, progression-free survival. ETHICS AND DISSEMINATION BRIOChe obtained ethical approval from Office for Research Ethics Committees Northern Ireland (reference no. 20/NI/0070). Final trial results will be published in peer-reviewed journals and adhere to the ICMJE guidelines. TRIAL REGISTRATION NUMBER ISRCTN60524.
Collapse
Affiliation(s)
- Eleanor M Hudson
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
| | - Samantha Noutch
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
| | - Joanne Webster
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
| | - Sarah R Brown
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
| | - Florien W Boele
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
- Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
| | | | - Helen Baines
- National Radiotherapy Trials QA (RTTQA) Group, Mount Vernon Cancer Centre, Northwood, UK
| | | | - Stuart Currie
- Department of Radiology, Leeds General Infirmary, Leeds, UK
| | - Sharon Fernandez
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
| | - Jane Hughes
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
| | - John Lilley
- Department of Medical Physics, Leeds Cancer Centre, Leeds, UK
| | - Alexandra Smith
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
| | | | - Finbar Slevin
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
- Department of Clinical Oncology, Leeds Cancer Centre, Leeds, UK
| | - Susan Short
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
- Department of Clinical Oncology, Leeds Cancer Centre, Leeds, UK
| | | | - Louise Murray
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
- Department of Clinical Oncology, Leeds Cancer Centre, Leeds, UK
| |
Collapse
|
2
|
Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med 2023; 29:2402-2405. [PMID: 37488293 DOI: 10.1038/s41591-023-02464-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/26/2023]
Affiliation(s)
- Kirit Singh
- The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
| | - Kelly M Hotchkiss
- The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
| | | | - John De Groot
- Division of Neuro-Oncology, Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, USA
| | | | - Nader Sanai
- Ivy Brain Tumor Center, The Barrow Neurological Institute, Phoenix, AZ, USA
| | - Michael Platten
- Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Michael Lim
- Department of Neurosurgery, Stanford University, School of Medicine, Stanford, CA, USA
| | - Patrick Y Wen
- Center for Neuro-Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
| | - Giuseppe Minniti
- Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy
| | - Howard Colman
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | - Timothy F Cloughesy
- Neuro-Oncology Program, University of California Los Angeles (UCLA), Los Angeles, CA, USA
| | | | | | | | - Annick Desjardins
- The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
| | - Kirk Tanner
- National Brain Tumor Society (NBTS), Newton, MA, USA
| | - Susan Short
- School of Medicine, University of Leeds, Leeds, UK
| | - David Arons
- National Brain Tumor Society (NBTS), Newton, MA, USA
| | | | - Wolfgang Wick
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurooncology, Heidelberg University, Heidelberg, Germany
| | - Stephen J Bagley
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - David M Ashley
- The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
| | - Priya Kumthekar
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Roel Verhaak
- School of Medicine, Yale University, New Haven, CT, USA
| | | | - Anoop P Patel
- The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
| | - Colin Watts
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - Peter E Fecci
- Surgical Neuro-Oncology, Department of Neurology, Duke University Medical Center, Durham, NC, USA
| | | | - Michael Weller
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Michael A Vogelbaum
- Department of NeuroOncology, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL, USA
| | - Matthias Preusser
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
| | - Mitchel S Berger
- Department of Neurological Surgery, UCSF Brain Tumor Center, San Francisco, CA, USA
| | - Mustafa Khasraw
- The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
| |
Collapse
|
3
|
Currie S, Fatania K, Frood R, Whitehead R, Start J, Lee MT, McDonald B, Rankeillor K, Roberts P, Chakrabarty A, Mathew RK, Murray L, Short S, Scarsbrook A. Imaging Spectrum of the Developing Glioblastoma: A Cross-Sectional Observation Study. Curr Oncol 2023; 30:6682-6698. [PMID: 37504350 PMCID: PMC10378288 DOI: 10.3390/curroncol30070490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 07/06/2023] [Accepted: 07/10/2023] [Indexed: 07/29/2023] Open
Abstract
Glioblastoma (GBM) has the typical radiological appearance (TRA) of a centrally necrotic, peripherally enhancing tumor with surrounding edema. The objective of this study was to determine whether the developing GBM displays a spectrum of imaging changes detectable on routine clinical imaging prior to TRA GBM. Patients with pre-operative imaging diagnosed with GBM (1 January 2014-31 March 2022) were identified from a neuroscience center. The imaging was reviewed by an experienced neuroradiologist. Imaging patterns preceding TRA GBM were analyzed. A total of 76 out of 555 (14%) patients had imaging preceding TRA GBM, 57 had solitary lesions, and 19 had multiple lesions (total = 84 lesions). Here, 83% of the lesions had cortical or cortical/subcortical locations. The earliest imaging features for 84 lesions were T2 hyperintensity/CT low density (n = 18), CT hyperdensity (n = 51), and T2 iso-intensity (n = 15). Lesions initially showing T2 hyperintensity/CT low density later showed T2 iso-intensity. When CT and MRI were available, all CT hyperdense lesions showed T2 iso-intensity, reduced diffusivity, and the following enhancement patterns: nodular 35%, solid 29%, none 26%, and patchy peripheral 10%. The mean time to develop TRA GBM from T2 hyperintensity was 140 days and from CT hyperdensity was 69 days. This research suggests that the developing GBM shows a spectrum of imaging features, progressing through T2 hyperintensity to CT hyperdensity, T2 iso-intensity, reduced diffusivity, and variable enhancement to TRA GBM. Red flags for non-TRA GBM lesions are cortical/subcortical CT hyperdense/T2 iso-intense/low ADC. Future research correlating this imaging spectrum with pathophysiology may provide insight into GBM growth patterns.
Collapse
Affiliation(s)
- Stuart Currie
- Department of Neuroradiology, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor B, Clarendon Wing, Great George Street, Leeds LS1 3EX, UK
- Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (L.M.); (S.S.); (A.S.)
| | - Kavi Fatania
- Radiology Academy, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor B, Clarendon Wing, Great George Street, Leeds LS1 3EX, UK; (K.F.); (R.F.); (R.W.); (J.S.); (M.-T.L.)
| | - Russell Frood
- Radiology Academy, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor B, Clarendon Wing, Great George Street, Leeds LS1 3EX, UK; (K.F.); (R.F.); (R.W.); (J.S.); (M.-T.L.)
| | - Ruth Whitehead
- Radiology Academy, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor B, Clarendon Wing, Great George Street, Leeds LS1 3EX, UK; (K.F.); (R.F.); (R.W.); (J.S.); (M.-T.L.)
| | - Joanna Start
- Radiology Academy, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor B, Clarendon Wing, Great George Street, Leeds LS1 3EX, UK; (K.F.); (R.F.); (R.W.); (J.S.); (M.-T.L.)
| | - Ming-Te Lee
- Radiology Academy, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor B, Clarendon Wing, Great George Street, Leeds LS1 3EX, UK; (K.F.); (R.F.); (R.W.); (J.S.); (M.-T.L.)
| | - Benjamin McDonald
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK; (B.M.); (K.R.); (P.R.); (A.C.)
| | - Kate Rankeillor
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK; (B.M.); (K.R.); (P.R.); (A.C.)
| | - Paul Roberts
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK; (B.M.); (K.R.); (P.R.); (A.C.)
| | - Aruna Chakrabarty
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK; (B.M.); (K.R.); (P.R.); (A.C.)
| | - Ryan K. Mathew
- Department of Neurosurgery, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Floor G, Jubilee Wing, Great George Street, Leeds LS1 3EX, UK
- School of Medicine, University of Leeds, Leeds LS2 9JT, UK
| | - Louise Murray
- Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (L.M.); (S.S.); (A.S.)
- Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK
| | - Susan Short
- Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (L.M.); (S.S.); (A.S.)
- Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF, UK
| | - Andrew Scarsbrook
- Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (L.M.); (S.S.); (A.S.)
- Department of Radiology, Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Bexley Wing, St James’s University Hospital, Leeds LS9 7TF, UK
| |
Collapse
|
4
|
Nicklin E, Phang I, Short S, Hoogendoorn P, Boele F. QOL-19. RETURNING TO WORK AFTER A BRAIN TUMOUR – “I THOUGHT I WOULD BE BACK AT WORK THE NEXT WEEK, HOW WRONG I WAS!”. Neuro Oncol 2022. [PMCID: PMC9660734 DOI: 10.1093/neuonc/noac209.946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
BACKGROUND
Returning to work is important for patients' and their families’ well-being, financial circumstances and quality of life. Side-effects of brain tumour (BT) treatment or clinical deterioration from BT progression often causes temporary or permanent inability to work. Aim: To explore the occupational expectations, experiences and satisfaction of BT patients (and their caregivers) following diagnosis/treatment.
METHODS
Qualitative semi-structured interviews were conducted with adults diagnosed with a primary BT, in employment/self-employed before diagnosis, currently in follow-up care; and their caregivers. Purposive sampling ensured a mixed BT sample. Participants were recruited from two UK tertiary referral hospitals. Data collection and thematic analysis are ongoing and will be completed by August 2022.
RESULTS
To date, 17 interviews (13 patient/4 caregiver) have taken place (59% female, aged 26-73,M= 43). Early findings: 1) Managing expectations: Patients underestimated the impact of surgery and how long it would take to return to work (if they had). Many would have liked more information prior to treatment about potential side-effects (e.g., extreme fatigue). 2) Prior financial support: Most patients suffered financially, often resulting in returning to work before they felt ready. Patients wanted more information prior to treatment about financial support. 3) Ongoing communication: Employers who were emotionally and practically supportive throughout the BT trajectory were highly valued. Some interviewees believed their employers needed to receive better education about BTs. 4) Flexible working: Patients returning to work with enhanced employer support (e.g., reduced hours, working from home and lighter duties) were more satisfied. 5) Better caregiver support: Many caregivers were unsupported by their employers to take carer leave, some worked more to support the family financially.
CONCLUSIONS
Preliminary findings offer novel data in an under-researched area. More knowledge around the experiences, barriers and facilitators influencing patients’ return to work will allow the planning of tailored occupational support and resources.
Collapse
Affiliation(s)
| | - Isaac Phang
- Lancashire Teaching Hospitals NHS Foundation Trust , Preston , United Kingdom
| | - Susan Short
- Leeds Teaching Hospitals NHS Trust , Leeds , USA
| | | | | |
Collapse
|
5
|
Boele F, Butler S, Nicklin E, Pointon L, Short S, Murray L. QOL-11. COMMUNICATION IN THE CONTEXT OF GLIOBLASTOMA TREATMENT: WHAT MATTERS MOST. Neuro Oncol 2022. [PMCID: PMC9660982 DOI: 10.1093/neuonc/noac209.938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
BACKGROUND
Given the poor prognosis of glioblastoma, it is critical that the benefits and burdens of treatments are clearly discussed with patients and family caregivers. We investigated experiences and preferences around glioblastoma treatment communication in patients, caregivers, and healthcare professionals (HCPs).
METHODS
Semi-structured qualitative interviews were conducted with adult glioblastoma patients, their caregivers, and HCPs. Purposive sampling was used to capture views across the entire disease trajectory and different specialties. Interviews were recorded, transcribed verbatim, and analysed thematically.
RESULTS
In total, 15 patients, 13 caregivers (in N=12 individual and N=8 dyadic interviews), and five HCPs participated (N=5 individual interviews). Four main themes were identified. 1) Communication practice and preferences. Risks and side-effects of anti-tumour treatments were explained clearly, with information layered and revisited frequently to aid understanding. Treatment was often understood to be ‘the only option’, particularly at recurrence. Understanding the impact of side-effects on daily life could be enhanced, including those from supportive medication (e.g., corticosteroids); alongside more proactive communication about support services. 2) What matters most. Patients/caregivers valued being well-supported by a trusted treatment team, feeling involved, having a sense of control, and quality of life. HCPs similarly highlighted trust, maintaining independence and quality of life, and emotional support as key. 3) Decision-making. With limited treatment options, trust and control are crucial in decision-making among patients, caregivers, and HCPs. While patients ultimately prefer to follow HCP advice they want to be involved, consider all alternatives, and voice what matters to them. 4) Impact of Covid-19. During the pandemic, greater efforts to maintain good communication were necessary. While negative impacts of Covid-19 were limited, caregivers appeared most disadvantaged by pandemic-related restrictions (e.g., limited visiting).
DISCUSSION
In glioblastoma treatment communication, building trusting relationships, maintaining a sense of control, and good support are identified by patients, caregivers, and HCPs as critical.
Collapse
Affiliation(s)
| | - Sean Butler
- University of Leeds , Leeds , United Kingdom
| | | | | | - Susan Short
- Leeds Teaching Hospitals NHS Trust , Leeds , USA
| | | |
Collapse
|
6
|
Tanner G, Finetti MA, Pollock S, Rippaus N, Bruns AF, Hogg C, Droop A, Bruning-Richardson A, Care M, Wilkinson J, Jenkinson M, Brodbelt A, Chakrabarty A, Ismail A, Short S, Stead L. IDHwt Glioblastomas Show Opposing Resistance Mechanisms Across Patients in Response to Standard Treatment. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac200.000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
AIMS
Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Despite aggressive treatment, a resistant tumour recurs in practically all patients. We therefore aimed to better understand the mechanisms driving this treatment resistance through investigating changes in gene expression across pairs of primary and recurrent GBM tumours.
METHOD
We generated or acquired bulk tumour RNA sequencing data for primary and first recurrent tumours from 107 patients who received standard treatment. Differential expression analysis between primary and recurrent samples found that the most dysregulated genes were involved in neurodevelopment and neurodifferentiation. We therefore used a publicly available ChIP-seq database to identify DNA binding factors for which binding sites are enriched in the promotors of genes with the largest expression changes from primary to recurrent.
RESULTS
Jumonji and AT-Rich Interacting Domain 2 (JARID2) was the most strongly enriched for binding to promotors of dysregulated genes. 65 patients showed an up-regulation and 42 showed a down-regulation of genes bound by this protein. The same set of JARID2 bound genes were found to be dysregulated in each direction, and correlated with the largest source of variation between samples in their response to treatment. Further enrichment analyses indicated that ‘Up’ responders may resist treatment through reduced proliferation and increased interaction with the tumour microenvironment, whereas ‘Down’ responders instead rely on a shift to mesenchymal cell states.
CONCLUSION
These results indicate that GBM tumours can be split into two subtypes that transcriptionally reprogramme in different directions through treatment and may benefit from different treatment approaches.
Collapse
Affiliation(s)
- Georgette Tanner
- Leeds Institute of Medical Research at St James’s; University of Leeds , UK
| | - Martina A Finetti
- Leeds Institute of Medical Research at St James’s; University of Leeds
| | - Steven Pollock
- Leeds Institute of Medical Research at St James’s; University of Leed
| | - Nora Rippaus
- Leeds Institute of Medical Research at St James’s; University of Leeds , UK
| | | | - Catherine Hogg
- Leeds Institute of Medical Research at St James’s; University of Leeds , UK
| | | | | | - Mathew Care
- Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds , UK
| | - Joseph Wilkinson
- Leeds Institute of Medical Research at St James’s; University of Leeds , UK
| | - Michael Jenkinson
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Andrew Brodbelt
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Aruna Chakrabarty
- Department of Histopathology, Leeds Teaching Hospital , Leeds , England
| | - Azzam Ismail
- Department of Histopathology, Leeds Teaching Hospital , Leeds , England
| | - Susan Short
- Leeds Institute of Medical Research at St James’s; University of Leeds , UK
| | - Lucy Stead
- Leeds Institute of Medical Research at St James’s; University of Leeds , UK
| |
Collapse
|
7
|
Short S, Kendall J, West E, Chalmers A, McBain C, Melcher A, Collinson F, Phillip R, Brown S, Samson A. P11.64.A Long-term follow up and translational data from the ReoGlio phase Ib trial of GM-CSF and intravenous pelareorep (Reovirus) alongside standard of care in GBM. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
We previously reported safety data from a phase Ib, open-label study of intravenous oncolytic virus pelareorep with GM-CSF alongside standard chemoradiotherapy in newly diagnosed glioblastoma confirming that the combination is well tolerated. We now report on long-term follow up and analysis of translational samples from tumour and blood in a subset of patients.
METHODS
15 patients with newly diagnosed GBM were treated with GM-CSF 50μg subcutaneously on days 1-3 and intravenous pelareorep on days 4-5 in weeks 1 and 4 of chemoradiotherapy, and subsequently in week 1 of each adjuvant temozolomide course: 7 patients received 1x1010TCID50 (dose level 1); 8 received 3x1010TCID50 (dose level 2). The primary objective was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy. Following a protocol amendment we also collected survival data in all patients up to August 2021. Serial blood samples were taken from three patients, at baseline, during chemoradiotherapy and in the first adjuvant cycle. Peripheral blood mononuclear cells were analysed for immune checkpoint expression by flow cytometry, RNAseq gene expression and T-cell receptor clonality, whilst plasma cytokines were quantified by Luminex.
RESULTS
This combination was well tolerated with 87% of patients completing treatment as planned. Survival data analysis showed that median OS was 12.6 months in dose level 1 and 16.1 months in dose level 2, median OS for all patients was 13.1 months. The 24-month survival estimate for all patients was 25.0%, 16.7% for dose level 1 and 33.3% for dose level 2. One patient in dose level 1 remains alive at 43 months post registration without further treatment. Laboratory data showed that pelareorep infusion resulted in inflammatory cytokine and chemokine secretion, immune checkpoint modulation, and upregulation of inflammatory pathways. There was also increased peripheral clonal tumour-specific T-cell proliferation following pelareorep infusion.
CONCLUSION
Although based on small numbers, these long-term follow up data suggest this may be an active combination in a subset of GBM patients. Translational data confirm that pelareorep potentially activates tumour-targeting immune pathways in GBM, with consequential immune checkpoint modulation. These data support a combination clinical trial of pelareorep, radiotherapy and immune checkpoint blockade in GBM.
Collapse
Affiliation(s)
- S Short
- University of Leeds , Leeds , United Kingdom
| | - J Kendall
- University of Leeds , Leeds , United Kingdom
| | - E West
- University of Leeds , Leeds , United Kingdom
| | - A Chalmers
- University of Glasgow , Glasgow , United Kingdom
| | - C McBain
- The Christie Hospital, Manchester , Manchester , United Kingdom
| | - A Melcher
- Institute of Cancer Research , London , United Kingdom
| | - F Collinson
- University of Leeds , Leeds , United Kingdom
| | - R Phillip
- University of Leeds , Leeds , United Kingdom
| | - S Brown
- University of Leeds , Leeds , United Kingdom
| | - A Samson
- University of Leeds , Leeds , United Kingdom
| |
Collapse
|
8
|
Marcus K, Balasubramaniam M, Short S, Sohn W. Cultural and linguistic disparities in dental utilisation in New South Wales, Australia. Community Dent Health 2022; 39:123-128. [PMID: 35333480 DOI: 10.1922/cdh_00275marcus06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE To examine the patterns and predictors of dental utilisation in culturally and linguistically diverse (CALD) and non-CALD groups in New South Wales. DESIGN Secondary analysis of the 2013 and 2015 NSW Adult Population Health Survey (n=24,707). MAIN OUTCOME Dental utilisation, defined as a dental visit within the last 12 months. CALD groups were defined using country of birth and language. Andersen's theoretical model was used. Chi-square test and multivariate logistic regression analysis adjusted for potential confounding. Sample weights adjusted for sampling design. RESULTS Most (69%) of the population were Australian born; 20% spoke a language other than English at home. Dental utilisation was 58.9% and 63.9% for CALD and non-CALD groups respectively. The foreign-born non-English speaking group had the highest level of education (60%) but lower levels of dental utilisation (OR:0.81, CI 0.69-0.94) than all groups. Australian born non-English speakers had similar levels of dental utilisation to the reference group (OR:1.27, CI 0.99-1.63). CONCLUSION There are significant disparities in dental care utilisation among CALD populations. Foreign born, non-English speaking CALD migrants, and people experiencing socioeconomic disadvantage, are at greatest risk of inadequate dental utilisation. Furthermore, the combination of predisposing factors, language and cultural barriers compound disparities in oral health care utilisation. This data highlights the need for oral healthcare services that are sensitive to population needs, to reduce disparities among CALD communities residing in NSW.
Collapse
Affiliation(s)
- K Marcus
- Population Oral Health, School of Dentistry, Faculty of Medicine & Health, The University of Sydney, Australia
| | - M Balasubramaniam
- Health Care Management, College of Business, Government and Law, Flinders University, South Australia
- Menzies Centre for Health Policy and Economics, School of Public Health, The University of Sydney, New South Wales
| | - S Short
- Discipline of Behavioural & Social Sciences in Health, Faculty of Medicine & Health, The University of Sydney, Australia
| | - W Sohn
- Population Oral Health, School of Dentistry, Faculty of Medicine & Health, The University of Sydney, Australia
| |
Collapse
|
9
|
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2022; 19:357-358. [PMID: 35322237 PMCID: PMC9038523 DOI: 10.1038/s41571-022-00623-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Michael Weller
- Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
| | - Martin van den Bent
- Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Matthias Preusser
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
| | - Emilie Le Rhun
- Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.,University of Lille, U1192, Lille, France.,Centre Hospitalier Universitaire (CHU) Lille, Neuro-Oncology, General and Stereotaxic Neurosurgery Service, Lille, France.,Oscar Lambret Center, Neurology, Lille, France
| | - Jörg C Tonn
- Department of Neurosurgery, University Hospital Munich LMU, Munich, Germany
| | - Giuseppe Minniti
- Radiation Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Martin Bendszus
- Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany
| | - Carmen Balana
- Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Spain
| | - Olivier Chinot
- Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille (APHM), CHU Timone, Department of Neuro-Oncology, Marseille, France
| | - Linda Dirven
- Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands
| | - Pim French
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands
| | - Monika E Hegi
- Department of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland
| | - Asgeir S Jakola
- Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg, Sweden
| | - Michael Platten
- Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany.,German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Patrick Roth
- Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
| | - Roberta Rudà
- Department of Neuro-Oncology, University Hospital, Turin, Italy
| | - Susan Short
- Leeds Institute of Medical Research, St James's University Hospital, Leeds, UK
| | - Marion Smits
- Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Martin J B Taphoorn
- Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.,Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands
| | - Andreas von Deimling
- Department for Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.,DKTK and Clinical Cooperation Unit Neuropathology, DKFZ, Heidelberg, Germany
| | - Manfred Westphal
- Department of Neurosurgery, University Hospital Hamburg, Hamburg, Germany
| | | | - Guido Reifenberger
- Department of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.,DKTK partner site Essen/Düsseldorf, Düsseldorf, Germany
| | - Wolfgang Wick
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.,DKTK and Clinical Cooperation Unit Neurooncology, DKFZ, Heidelberg, Germany
| |
Collapse
|
10
|
Pagett CJ, Lilley J, Lindsay R, Short S, Murray L. Optimising tumour coverage and organ at risk sparing for hypofractionated re-irradiation in glioblastoma. Phys Imaging Radiat Oncol 2022; 21:84-89. [PMID: 35243037 PMCID: PMC8881705 DOI: 10.1016/j.phro.2022.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 02/16/2022] [Accepted: 02/17/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND AND PURPOSE Re-irradiation may be used for recurrent glioblastoma (GBM) patients. In some cases Planning Target Volume (PTV) under-coverage is necessary to meet organ at risk (OAR) constraints. This study aimed to develop a Volumetric Modulated Arc Therapy planning solution for GBM re-irradiation including a means of assessing if target coverage would be achievable and how much PTV 'cropping' would be required to meet OAR constraints, based on PTV volume and OAR proximity. MATERIALS AND METHODS For 10 PTVs, 360°, 180°, two coplanar 180° and 180° + non-coplanar 45° arc arrangements were compared using 35 Gy in 10 fractions. Using the preferred arrangement, dose fall-off was modelled to determine the separation required between PTV and OAR to ensure OAR dose constraints were met, with data presented graphically. To evaluate the graph as an aid to planning, seven cases with overlap were replanned in two treatment planning systems (TPSs). RESULTS There were no significant dosimetric differences between arc arrangements. 180° was preferred due to shorter treatment times. The graph, which indicated if 95% PTV coverage would be achievable based on PTV volume and OAR proximity, was employed in seven cases to guide planning in two TPSs. Plans were deliverable. CONCLUSIONS Re-irradiation treatment planning can be challenging, especially when PTV under-coverage is necessary. 180° was considered optimal. To assist in the planning process, graphical guidance was produced to inform planners whether PTV under-coverage would be necessary and how much PTV 'cropping' would be required to meet constraints during optimisation.
Collapse
Affiliation(s)
| | - John Lilley
- Leeds Teaching Hospitals NHS Trust, United Kingdom
| | | | - Susan Short
- Leeds Teaching Hospitals NHS Trust, United Kingdom
- Leeds Institute of Medical Research, University of Leeds, United Kingdom
| | - Louise Murray
- Leeds Teaching Hospitals NHS Trust, United Kingdom
- Leeds Institute of Medical Research, University of Leeds, United Kingdom
| |
Collapse
|
11
|
Frances SM, Klein M, Short S, Murray L, Velikova G, Wright J, Boele F. QOLP-14. LONG-TERM IMPACT OF ADULT GLIOMA ON HEALTH-RELATED QUALITY OF LIFE: A SYSTEMATIC REVIEW. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Glioma diagnosis can be devastating, and results in a wide range of symptoms. Relatively little is known about the long-term challenges these symptoms pose on HRQOL. The aim of this review is to identify the long-term HRQOL issues reported at least two years following diagnosis of glioma.
METHOD
Systematic literature searches were carried out using Medline, EMBASE, CINAHL, PsycINFO, and Web of Science Core Collection. Searches were designed to identify a range of reported HRQOL aspects defined as physical, mental or social issues, in adult WHO grade II or III patients. To capture the full extent of patients’ experience, studies of any design reporting on primary data where patients had at least two years follow-up from diagnosis were included. WHO grade I and grade IV tumours were excluded due to their different prognoses and the expected nature of their disease trajectories. Narrative synthesis was used to collate findings.
RESULTS
The search returned 8438 articles. 477 titles remained after title and abstract screening, with seventeen full text articles included in the final analysis. The majority of studies used quantitative methods, with only two articles reporting qualitative or mixed methodology. Articles were predominantly cross-sectional studies (n = 9), along with cohort studies (n = 3), clinical trials (n = 3) and pilot studies (n = 2). Results indicated that patients reported a variety of issues influencing their HRQOL, with emotional/psychological/cognitive changes the most frequently reported. Physical complaints included problems with fatigue, seizures and maintaining daily activity. Social challenges included strained social relationships and issues managing finances. Patient coping strategies were found to significantly influence wellbeing and subsequent HRQOL.
CONCLUSION
Glioma patients’ long-term HRQOL and daily functioning can be impacted by their physical, mental and social wellbeing. Findings from this review lay the groundwork for efforts to improve patient long-term HRQOL.
Collapse
Affiliation(s)
| | - Martin Klein
- VU University Medical Center, Amsterdam, Netherlands
| | | | | | | | | | | |
Collapse
|
12
|
Frances S, Velikova G, Klein M, Short S, Murray L, Wright J, Boele F. P11.02 Long-term impact of primary brain tumour diagnosis on health-related quality of life: a systematic review. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
BACKGROUND
A primary brain tumour (PrBT) diagnosis can be devastating, and results in a wide range of symptoms. Relatively little is known about the long-term challenges these symptoms pose on HRQOL. The aim of this review is to identify the long-term HRQOL issues reported at least two years following diagnosis of a PrBT.
MATERIAL AND METHODS
Systematic literature searches were carried out using Medline, EMBASE, CINAHL, PsycINFO and Web of Science Core Collection. Searches were designed to identify a range of reported HRQOL aspects defined as physical, mental or social issues, in adult WHO grade II or III patients. To capture the full extent of patients’ experience, studies of any design reporting on primary data where patients had at least two years follow-up from diagnosis were included. WHO grade I and grade IV tumours were excluded due to their different prognoses and the expected nature of their disease trajectories. Quality assessment was conducted using the Mixed Methods Appraisal Tool (MMAT). Narrative synthesis was used to collate findings.
RESULTS
The search returned 8438 articles. 477 titles remained after title and abstract screening, with eighteen full text articles included in the final analysis. The majority of studies used quantitative methods, with only two articles reporting qualitative or mixed methodology. Articles were predominantly cross-sectional studies (n = 10), along with cohort studies (n = 3), clinical trials (n = 3) and pilot studies (n = 2). Results indicated that patients reported a variety of issues influencing their HRQOL, with emotional/psychological/cognitive changes being the most commonly reported. Physical complaints included problems with fatigue, seizures and maintaining daily activity. Social challenges included strained social relationships and issues managing finances. Patient coping strategies were found to significantly influence wellbeing and subsequent HRQOL.
CONCLUSION
PrBT patients’ long-term HRQOL and daily functioning can be impacted by their physical, mental and social wellbeing. Findings from this review lay the groundwork for efforts to improve patient HRQOL in long-term survivorship.
Collapse
Affiliation(s)
- S Frances
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
| | - G Velikova
- University of Leeds, St James Institute of Oncology, Leeds, United Kingdom
| | - M Klein
- Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - S Short
- University of Leeds, St James Institute of Oncology, Leeds, United Kingdom
| | - L Murray
- Leeds Institute of Molecular Research, University of Leeds, Leeds, United Kingdom
- Department of Clinical Oncology, Leeds Cancer Centre, Leeds, United Kingdom
| | - J Wright
- Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
| | - F Boele
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
| |
Collapse
|
13
|
McKelvey KJ, Wilson EB, Short S, Melcher AA, Biggs M, Diakos CI, Howell VM. Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma. Front Oncol 2021; 11:633210. [PMID: 33854970 PMCID: PMC8039392 DOI: 10.3389/fonc.2021.633210] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 02/10/2021] [Indexed: 01/18/2023] Open
Abstract
Glioblastoma (GBM) is the most aggressive adult glioma with a median survival of 14 months. While standard treatments (safe maximal resection, radiation, and temozolomide chemotherapy) have increased the median survival in favorable O(6)-methylguanine-DNA methyltransferase (MGMT)-methylated GBM (~21 months), a large proportion of patients experience a highly debilitating and rapidly fatal disease. This study examined GBM cellular energetic pathways and blockade using repurposed drugs: the glycolytic inhibitor, namely dicholoroacetate (DCA), and the partial fatty acid oxidation (FAO) inhibitor, namely ranolazine (Rano). Gene expression data show that GBM subtypes have similar glucose and FAO pathways, and GBM tumors have significant upregulation of enzymes in both pathways, compared to normal brain tissue (p < 0.01). DCA and the DCA/Rano combination showed reduced colony-forming activity of GBM and increased oxidative stress, DNA damage, autophagy, and apoptosis in vitro. In the orthotopic Gl261 and CT2A syngeneic murine models of GBM, DCA, Rano, and DCA/Rano increased median survival and induced focal tumor necrosis and hemorrhage. In conclusion, dual targeting of glycolytic and FAO metabolic pathways provides a viable treatment that warrants further investigation concurrently or as an adjuvant to standard chemoradiation for GBM.
Collapse
Affiliation(s)
- Kelly J McKelvey
- Bill Walsh Translational Cancer Research Laboratory, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia
| | - Erica B Wilson
- Translational Neuro-Oncology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom
| | - Susan Short
- Translational Neuro-Oncology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom
| | - Alan A Melcher
- Translational Immunotherapy, Division of Radiotherapy and Imaging, Institute for Cancer Research, London, United Kingdom
| | - Michael Biggs
- Department of Neurosurgery, North Shore Private Hospital, St Leonards, NSW, Australia
| | - Connie I Diakos
- Bill Walsh Translational Cancer Research Laboratory, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia.,Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.,Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia
| | - Viive M Howell
- Bill Walsh Translational Cancer Research Laboratory, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia
| |
Collapse
|
14
|
Kendall J, Chalmers A, McBain C, Melcher A, Samson A, Phillip R, Brown S, Short S. CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Oncolytic viruses represent a novel treatment approach in GBM through oncolytic targeting as well as local immune activation. We designed a phase Ib, open-label study of intravenous reovirus (pelareorep) with GM-CSF alongside standard chemoradiotherapy to assess safety and tolerability.
METHODS
15 patients with newly diagnosed GBM were treated with GM-CSF 50mg subcutaneously (days 1–3) and pelareorep (days 4–5) in weeks 1 and 4 of chemoradiotherapy, and week 1 of adjuvant temozolomide course: 7 patients received 1x1010TCID50 (dose level 1); 8 received 3x1010TCID50 (dose level 2). The primary objective was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy. Secondary objectives were to gain preliminary assessment of the activity of the combination and assess treatment compliance.
RESULTS
1 dose limiting toxicity (DLT) and 20 SAEs were experienced overall; median number of SAEs per patient was 2. Commonest SAEs were nervous system disorders, predominantly seizures. SARs included fever/flu-like episodes (n=5), fall (n=1) and headache (n=1). Two SUSARs occurred in dose level 2, classed as vascular disorders manifesting as hypotension episodes – one was a DLT. Suspected relationship of SARs: pelareorep (n=6); temozolomide (n=1); radiotherapy (n=1); all study drugs (n=1). 87% of patients (n=13) completed chemoradiotherapy without unplanned delays. Adjuvant treatment was delayed in 21% of cycles overall, with the majority due to inadequate haematology/biochemistry values (44% of delays). Pelareorep was omitted in 4 instances in 4 patients during chemoradiotherapy and omitted in 4 instances in 3 patients during adjuvant treatment.
CONCLUSION
We present the first clinical data using intravenous pelareorep with GM-CSF alongside standard chemoradiotherapy in patients with GBM, suggesting that the combination is tolerable. Further analysis is underway and efficacy results will be ready for presentation at the conference. This work was supported by CRUK, The Brain Tumour Charity, Yorkshire Cancer Research and Oncolytics Biotech Inc.
Collapse
Affiliation(s)
| | | | | | - Alan Melcher
- The Royal Marsden/Institute of Cancer Research National Institute of Health Research Biomedical Research Centre, London, United Kingdom
| | - Adel Samson
- Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, United Kingdom
| | | | - Sarah Brown
- CTRU, University of Leeds, Leeds, United Kingdom
| | - Susan Short
- Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, United Kingdom
| |
Collapse
|
15
|
Swendener B, Short S, Dedio R. 251 Peritonsillar Abscess Treatment Within Emergency Departments. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Le Rhun E, Weller M, Niclou SP, Short S, Piil K, Boele F, Rudà R, Theodorou M, Brandsma D, van den Bent M, Dirven L. Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. Neurooncol Pract 2020; 7:249-259. [PMID: 32206322 DOI: 10.1093/nop/npz053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Women represent an increasing proportion of the overall workforce in medicine but are underrepresented in leadership roles. Methods To explore gender inequalities and challenges in career opportunities, a web-based survey was conducted among the membership of the European Association of Neuro-Oncology and the Brain Tumor Group of the European Organisation for Research and Treatment of Cancer. Results A total of 228 colleagues responded to the survey: 129 women (median age 45 years; range, 25-66 years) and 99 men (median age 48 years; range, 24-81 years); 153 participants (67%) were married and 157 participants (69%) had at least 1 child. Women less often declared being married (60% vs 77%, P = .007) or having a child (63% vs 77%, P = .024). Men more frequently had a full-time position (88% vs 75%, P = .036). Women and men both perceived an underrepresentation of women in leadership positions. Half of participants agreed that the most important challenges for women are leading a team and obtaining a faculty position. Fewer women than men would accept such a position (42% vs 56%). The main reasons were limited time for career and an inappropriate work and life balance. Women specifically cited negative discrimination, limited opportunities, and lack of self-confidence. Discrimination of women at work was perceived by 64% of women vs 47% of men (P = .003). Conclusion Women are perceived as experiencing more difficulties in acquiring a leadership position. Personal preferences may account for an underrepresentation of women in leadership positions, but perceived gender inequalities extend beyond disparities of access to leadership.
Collapse
Affiliation(s)
- Emilie Le Rhun
- University of Lille, France.,Inserm, Lille, France.,CHU Lille, General and Stereotaxic Neurosurgery Service, France.,Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Switzerland
| | - Michael Weller
- Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Switzerland
| | - Simone P Niclou
- NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health
| | - Susan Short
- Leeds Institute of Medical Research at St James's, St James's University Hospital, United Kingdom.,Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, United Kingdom
| | - Karin Piil
- Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark
| | - Florien Boele
- Leeds Institute of Medical Research at St James's, St James's University Hospital, United Kingdom.,Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, United Kingdom
| | - Roberta Rudà
- Department of Neuro-Oncology, City of Health and Science and University of Turin, Italy
| | - Marilena Theodorou
- Radiation Oncology, Department in Bank of Cyprus Oncology, Center and Health of Science, European University Cyprus, Amsterdam, the Netherlands
| | - Dieta Brandsma
- Department of Neuro-Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| | - Martin van den Bent
- Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
| | - Linda Dirven
- Department of Neurology, Leiden University Medical Center, the Netherlands.,Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands
| |
Collapse
|
17
|
Fernandez S, Murray L, Scarsbrook A, Broadbent D, Shelley D, Currie S, Short S. The impact of the neuro-oncology research radiographer role in the effective facilitation of an advanced imaging study in glioblastoma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz167.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
A neuro-oncology research radiographer was included in the multi-disciplinary study team (MDT) from the set-up stage of a new advanced imaging study in glioblastoma, as it was envisaged that this would enhance progress and provide better patient-centred care.
Aims
This pilot study aimed to include 12 participants. This specialist radiographer role was to support recruitment, co-ordinate appointments and monitor patients’ progress. We aimed to ensure that optimal treatment and patient-centred care remained at the forefront of the study pathway.
Method
Patients were identified and approached by the radiographer prior to consent by a trial investigator. Additional scans were planned prior to radiotherapy (RT), 2 weeks into RT and 6 weeks post RT. The radiographer ensured streamlined appointments and was present during each study visit to liaise with health professionals, provide a specific point of contact with the patient and to ensure continuity.
Results
6 patients have been recruited since November 2018. The specialist radiographer has attended 28 study scans to date. Over 40 face-to-face interactions have been undertaken, 30 email communications and 18 telephone consultations. Patient feedback has been extremely positive, all patients convey that they feel supported and value continuity throughout the pathway. Enhanced communication across the entire study team has also guaranteed efficient recruitment.
Conclusion
The research radiographer has a key role in the multi-disciplinary team delivering this study. Effective liaison between the radiotherapy and imaging departments has been crucial and patients value a consistent point of contact through the study and treatment pathways.
Collapse
Affiliation(s)
| | - Louise Murray
- University of Leeds, St James’s Hospital and Leeds Institute of Medical Research, Leeds, United Kingdom
| | - Andrew Scarsbrook
- University of Leeds, St James’s Hospital and Leeds Institute of Medical Research, Leeds, United Kingdom
| | | | | | | | - Susan Short
- University of Leeds, St James’s Hospital and Leeds Institute of Medical Research, Leeds, United Kingdom
| |
Collapse
|
18
|
Bruns AF, Rippaus N, Droop A, Al-Jabri M, Care M, Jenkinson M, Brodbelt A, Chakrabarty A, Ismail A, Short S, F Stead L. Chromatin remodelling to facilitate treatment resistance in glioblastoma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz167.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Recent findings from our group, and the wider community, show that standard treatment does not impose an apparent bottleneck on the clonal evolution of adult glioblastoma (GBM), implying a lack of direct therapeutic opportunity. This does not negate the possibility that multiple treatment-resistance mechanisms co-exist in tumours, repeated across patients, making a combination of targeted therapies a potentially effective approach. We investigated whether treatment resistance may be driven by selection of cellular properties conferred above the level of the genome. Differential expression analysis was performed on 23 pairs of primary and recurrent tumours from patients who received standard treatment and had a local recurrence treated by surgery and second line chemotherapy. This revealed a treatment-induced shift in cell states linked to normal neurodevelopment. The latter is orchestrated by cascades of transcription factors. We, therefore, applied a bespoke gene set enrichment analysis to our paired expression data to investigate whether any factors were implicated in co-regulation of the genes that were altered through therapy. This identified a specific chromatin remodelling machinery, instrumental in normal neurogenesis. We validated our results in an independent cohort of 22 paired GBM samples. Our results suggest that the chromatin remodelling machinery is responsible for determining transcriptional hierarchies in GBM, shown elsewhere to have different treatment sensitivities such that their relative abundances are altered through treatment.
Collapse
Affiliation(s)
- Alexander-F Bruns
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom
| | - Nora Rippaus
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
| | - Alastair Droop
- Leeds Institute of Data Analytics, University of Leeds, Leeds, United Kingdom
| | - Muna Al-Jabri
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
| | - Matthew Care
- Leeds Institute of Data Analytics, University of Leeds, Leeds, United Kingdom
| | - Michael Jenkinson
- Walton Centre NHS Trust, Liverpool, United Kingdom
- Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
| | - Andrew Brodbelt
- Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, United Kingdom
| | - Aruna Chakrabarty
- Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, United Kingdom
| | - Azzam Ismail
- Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, United Kingdom
| | - Susan Short
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
- Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, United Kingdom
| | - Lucy F Stead
- Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom
| |
Collapse
|
19
|
Rippaus N, Manning J, Droop A, Al-Jabri M, Care M, Bruns AF, Jenkinson MD, Brodbelt A, Chakrabarty A, Ismail A, Short S, Stead LF. OS9.5 Evidence that adult glioblastoma adapts to standard therapy though chromatin remodeling. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Glioblastoma (GBM) tumours recur following standard treatment in almost all cases. We use ‘omics technologies to simultaneously profile pairs of primary and matched recurrent GBM to specifically identify and characterise the cells that resisted treatment, with the aim of determining how to more effectively kill them.
MATERIAL AND METHODS
We have analysed high coverage RNAseq data from pairs of GBM tumours: primary de novo tumour and matched local recurrence from patients that underwent standard therapy. Our original cohort constituted 23 pairs and our validation cohort was an additional 22 pairs. We also cultured two plates of spheroids directly from a patient’s GBM, treating one with radiation and temozolomide. We monitored growth and captured and sequenced RNA from single cells at two time-points: one week post-treatment when the deviation between untreated and treated spheroid growth curves was most pronounced; and three weeks post-treatment when the growth rate of treated spheroids had recovered. We investigated differential gene expression between primary and recurrent pairs, and single cells pre- and post-treatment, and performed a bespoke per patient gene set enrichment analysis.
RESULTS
Differential gene expression analysis in 23 tumour pairs indicated a treatment-induced shift in cell states linked to normal neurogenesis and prompted us to develop a novel gene set enrichment analysis approach to identify gene regulatory factors that may orchestrate such a shift. This revealed the significant and universal dysregulation of genes, through therapy, that are targeted by a specific chromatin remodeling machinery. This finding was validated in an independent cohort of 22 further GBM pairs. To understand the therapeutic potential of this finding we must determine whether genes are dysregulated through therapy owing to a) their fixed expression in inherently treatment resistance cells in the primary tumour which get selected during therapy to increase the signal of that profile, or b) changes in expression during the process of cells acquiring treatment resistance. To inspect this, we analysed single cell gene expression data from GBM spheroids pre- and post-treatment. We found that there was significant dysregulation of the genes associated with the chromatin remodeling complex but only at the three-week post-treatment time-point.
CONCLUSION
Our results indicate that GBM cells are being transcriptionally reprogrammed in response to treatment; the mechanism of which may represent a therapeutic opportunity.
Collapse
Affiliation(s)
- N Rippaus
- Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom
| | - J Manning
- Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom
| | - A Droop
- Leeds Institute of Data Analytics, Leeds, United Kingdom
| | - M Al-Jabri
- Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom
| | - M Care
- Leeds Institute of Data Analytics, Leeds, United Kingdom
| | - A F Bruns
- Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom
- Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, United Kingdom
| | - M D Jenkinson
- Walton Centre NHS Trust, Liverpool, United Kingdom
- Institute of Translational Medicine, Liverpool, United Kingdom
| | - A Brodbelt
- Walton Centre NHS Trust, Liverpool, United Kingdom
| | - A Chakrabarty
- Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
| | - A Ismail
- Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
| | - S Short
- Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom
| | - L F Stead
- Leeds Institute of Medical Research at St James’s, Leeds, United Kingdom
| |
Collapse
|
20
|
Bruning-Richardson A, Sanganee H, Barry S, Tams D, Brend T, King H, Morton R, Ward T, Steele L, Shaw G, Esteves F, Droop A, Lawler S, Short S. PL3.6 Targeting GSK-3 activity promotes mitotic catastrophe via centrosome destabilisation and enhances the effect of radiotherapy in glioma models. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Targeting kinases as regulators of cellular processes that drive cancer progression is a promising approach to improve patient outcome in GBM management. The glycogen synthase kinase 3 (GSK-3) plays a role in cancer progression and is known for its pro-proliferative activity in gliomas. The anti-proliferative and cytotoxic effects of the GSK-3 inhibitor AZD2858 were assessed in relevant in vitro and in vivo glioma models to confirm GSK-3 as a suitable target for improved single agent or combination treatments.
MATERIAL AND METHODS
The immortalised cell line U251 and the patient derived cell lines GBM1 and GBM4 were used in in vitro studies including MTT, clonogenic survival, live cell imaging, immunofluorescence microscopy and flow cytometry to assess the cytotoxic and anti-proliferative effects of AZD2858. Observed anti-proliferative effects were investigated by microarray technology for the identification of target genes with known roles in cell proliferation. Clinical relevance of targeting GSK-3 with the inhibitor either for single agent or combination treatment strategies was determined by subcutaneous and orthotopic in vivo modelling. Whole mount mass spectroscopy was used to confirm drug penetration in orthotopic tumour models.
RESULTS
AZD2858 was cytotoxic at low micromolar concentrations and at sub-micromolar concentrations (0.01 - 1.0 μM) induced mitotic defects in all cell lines examined. Prolonged mitosis, centrosome disruption/duplication and cytokinetic failure leading to cell death featured prominently among the cell lines concomitant with an observed S-phase arrest. No cytotoxic or anti-proliferative effect was observed in normal human astrocytes. Analysis of the RNA microarray screen of AZD2858 treated glioma cells revealed the dysregulation of mitosis-associated genes including ASPM and PRC1, encoding proteins with known roles in cytokinesis. The anti-proliferative and cytotoxic effect of AZD2858 was also confirmed in both subcutaneous and orthotopic in vivo models. In addition, combination treatment with AZD2858 enhanced clinically relevant radiation doses leading to reduced tumour volume and improved survival in orthotopic in vivo models.
CONCLUSION
GSK-3 inhibition with the small molecule inhibitor AZD2858 led to cell death in glioma stem cells preventing normal centrosome function and promoting mitotic failure. Normal human astrocytes were not affected by treatment with the inhibitor at submicromolar concentrations. Drug penetration was observed alongside an enhanced effect of clinical radiotherapy doses in vivo. The reported aberrant centrosomal duplication may be a direct consequence of failed cytokinesis suggesting a role of GSK-3 in regulation of mitosis in glioma. GSK-3 is a promising target for combination treatment with radiation in GBM management and plays a role in mitosis-associated events in glioma biology.
Collapse
Affiliation(s)
| | | | - S Barry
- Astra Zeneca, Cambridge, United Kingdom
| | - D Tams
- University of Leeds, Leeds, United Kingdom
| | - T Brend
- University of Leeds, Leeds, United Kingdom
| | - H King
- University of Leeds, Leeds, United Kingdom
| | - R Morton
- University of Leeds, Leeds, United Kingdom
| | - T Ward
- University of Leeds, Leeds, United Kingdom
| | - L Steele
- University of Leeds, Leeds, United Kingdom
| | - G Shaw
- University of Leeds, Leeds, United Kingdom
| | - F Esteves
- University of Leeds, Leeds, United Kingdom
| | - A Droop
- University of Leeds, Leeds, United Kingdom
| | - S Lawler
- Harvard University, Boston, MA, United States
| | - S Short
- University of Leeds, Leeds, United Kingdom
| |
Collapse
|
21
|
Salvatore D, Shaw G, Wright J, Teh I, Koch-Paszkowski J, Murray L, Scarsbrook A, Schneider J, Ottobrini L, Short S. P11.13 Radiotherapy combined with a multimodal imaging approach in a glioblastoma preclinical model. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Glioblastoma multiforme (GBM) carries a poor prognosis, partly due to biological and anatomical heterogeneity. Although radiotherapy (RT) is effective, high doses damage surrounding healthy tissues. Multimodal imaging with Magnetic Resonance (MRI) and Positron Emission Tomography (PET) may represent a useful approach for identifying GBM heterogeneity and visualising metabolic tumour properties. PET radiotracer [18F]-fluciclovine is preferentially accumulated in gliomas compared to healthy brain tissue via the cellular transport systems, LAT1 and ASCT2. In this study the effect of fractionated RT using multimodal imaging including [18F]-fluciclovine uptake and immunohistochemistry (IHC) in a GBM preclinical model will be validated.
MATERIAL AND METHODS
Two C57BL/6J mice cohorts were injected intracranially (i.c.) with murine CT2A-luc cells and subsequently submitted to multiparametric MRI and [18F]-fluciclovine PET imaging during hemi-brain RT (3Gy on 2 days/each week) for maximum 25 days after i.c. injection. Brains were collected for IHC characterization including LAT1 and ASCT2 staining.
RESULTS
Preliminary data showed that both MRI and PET were effective modalities to track tumour growth in this model. PET data revealed up to greater than 3-fold increase in SUVmax from regions of interest around the tumour site compared to healthy brain tissue. Time activity curves showed a steady increase in tumour uptake over 90 minutes. MRI showed a 25% increase in T2 values in tumours relative to unaffected contralateral regions. Confirmation of treatment response through matched imaging and IHC are ongoing, from which changes in glioma cell biology as well as amino acid transporter protein levels will be analysed.
CONCLUSION
These preliminary results show that multimodal imaging presents novel data in the assessment of treatment response in this model and will permit parallel IHC analyses to better define GBM tumour heterogeneity aligned with imaging changes. These data will also inform an on-going clinical study using the same imaging modalities.
Work at authors’ labs are supported by an Investigator initiated project from Blue Earth Diagnostics (AS, SCS) and a University of Leeds Biswas studentship (SCS, DS). Daniela Salvatore is also supported by a Scholarship provided by Molecular and Translational Medicine Doctorate School of University of Milan (Italy).
Collapse
Affiliation(s)
- D Salvatore
- Leeds Institute of Medical Research (LIMR), Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
- Department of Pathophysiology and Transplantation, University of Milan, Segrate, Milan, Italy
| | - G Shaw
- Leeds Institute of Medical Research (LIMR), Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
| | - J Wright
- Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, United Kingdom
| | - I Teh
- Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, United Kingdom
| | - J Koch-Paszkowski
- Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, United Kingdom
| | - L Murray
- Leeds Institute of Medical Research (LIMR), Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
| | - A Scarsbrook
- Leeds Institute of Medical Research (LIMR), Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
| | - J Schneider
- Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, United Kingdom
| | - L Ottobrini
- Department of Pathophysiology and Transplantation, University of Milan, Segrate- Molecular Bioimaging and Physiology (IBFM), CNR, Segrate, Milan, Italy
| | - S Short
- Leeds Institute of Medical Research (LIMR), Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
| |
Collapse
|
22
|
Nassiri F, Aldape K, Alhuwalia M, Brastianos P, Ducray F, Galldiks N, Kim A, Lamszus K, Mitchell D, Nabors LB, Nam DH, Natsume A, Ng HK, Niclou S, Sahm F, Short S, Walsh K, Wick W, Zadeh G. Highlights of the inaugural ten - the launch of Neuro-Oncology Advances. Neurooncol Adv 2019; 1:vdz016. [PMID: 32642652 DOI: 10.1093/noajnl/vdz016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Farshad Nassiri
- Division of Neurosurgery, University Health Network and MacFeeters-Hamilton Neuro-Oncology Program, Princess Margaret Hospital, University of Toronto, Toronto, Canada
| | - Kenneth Aldape
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
| | - Manmeet Alhuwalia
- Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center and Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
| | - Priscilla Brastianos
- Divisions of Hematology/Oncology and Neuro-Oncology, Departments of Medicine and Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Francois Ducray
- Department of Neuro-Oncology, Hospices Civils de Lyon, Lyon, France
| | - Norbert Galldiks
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne and Germany Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich and Germany Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
| | - Albert Kim
- Department of Neurosurgery, School of Medicine, Washington University, St. Louis, Missouri
| | - Katrin Lamszus
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Duane Mitchell
- Lillian S. Wells Department of Neurosurgery, UF Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, Florida
| | - L Burt Nabors
- Department of Neurology, University of Alabama, Birmingham, Birmingham, Alabama
| | - Do-Hyun Nam
- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea
| | - Atsushi Natsume
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China
| | - Simone Niclou
- Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany
| | - Felix Sahm
- NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Susan Short
- Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Leeds, West Yorkshire
| | - Kyle Walsh
- Duke Cancer Institute, Duke University, Durham, North Carolina
| | - Wolfgang Wick
- University Medical Center and German Cancer Research Center Heidelberg, Germany
| | - Gelareh Zadeh
- Division of Neurosurgery, University Health Network and MacFeeters-Hamilton Neuro-Oncology Program, Princess Margaret Hospital, University of Toronto, Toronto, Canada
| |
Collapse
|
23
|
Morgan R, Primon M, Shnyder S, Short S, Kaur B, Hong B, Bagwan I, Rogers W, Pandha HS. Abstract 5215: Targeting of HOX-PBX binding in glioblastoma multiforme as a novel therapeutic treatment. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-5215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The HOX genes encode a family of transcription factors that play an essential role in embryonic patterning. They are also aberrantly expressed in numerous cancers, including glioblastoma (GBM). Three Amino Acid Loop Extension Homeobox (TALE) proteins act as important co-factors for HOX proteins, modulating their binding affinities to genomic targets. TALE proteins include the Pre-B-cell leukemia homeobox (PBX) proteins 1-4, which bind anterior HOX proteins, facilitating their nuclear entry and limiting their degradation. HTL00-1 is a 2nd generation hexapeptide drug that inhibits HOX-PBX dimer formation, and has been shown to induce rapid apoptosis in cancer cells, but not normal cells, through the rapid upregulation of genes including cFos, DUSP1, and EGR1. We have found that both HOX and TALE genes are markedly dysregulated in primary GBM tumors as well as in murine (GL261), adult (LN18, U87-MG, U251-MG) and pediatric (KNS42, SF188) GBM cell lines, all of which are sensitive to HTL-001. These genes were even more highly expressed in experimentally induced GBM cancer stem cells (CSCs) compared with parental lines, with a corresponding increase in sensitivity to HTL-001. We also investigated the in vivo activity of HTL-001 in Black 6 mice carrying GL-261 subcutaneous and orthotropic tumors with twice weekly intraperitoneal delivery. HTL-001 was shown to cross the blood brain barrier using Alexa660 labelled peptide, and significant anti-tumor activity was observed in both subcutaneous and orthotropic models with increased survival (p<0.02 and p<0.0078, respectively). Resected tumors from HTL-001 treated mice showed marked evidence of apoptosis, tumor vasculature disruption and focal necrosis compared to untreated tumors. Taken together, our findings indicate that HOX-PBX inhibition is a potential therapeutic target for adult and pediatric GBM patients.
Citation Format: Richard Morgan, Monika Primon, Steven Shnyder, Susan Short, Balveen Kaur, Bangxing Hong, Izhar Bagwan, William Rogers, Hardev S. Pandha. Targeting of HOX-PBX binding in glioblastoma multiforme as a novel therapeutic treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5215.
Collapse
|
24
|
Abstract
Cell senescence is a driver of ageing, frailty, age-associated disease and functional decline. In oncology, tumour cell senescence may contribute to the effect of adjuvant therapies, as it blocks tumour growth. However, this is frequently incomplete, and tumour cells that recover from senescence may gain a more stem-like state with increased proliferative potential. This might be exaggerated by the induction of senescence in the surrounding niche cells. Finally, senescence will spread through bystander effects, possibly overwhelming the capacity of the immune system to ablate senescent cells. This induces a persistent system-wide senescent cell accumulation, which we hypothesize is the cause for the premature frailty, multi-morbidity and increased mortality in cancer survivors. Senolytics, drugs that selectively kill senescent cells, have been developed recently and have been proposed as second-line adjuvant tumour therapy. Similarly, by blocking accelerated senescence following therapy, senolytics might prevent and potentially even revert premature frailty in cancer survivors. Adjuvant senostatic interventions, which suppress senescence-associated bystander signalling, might also have therapeutic potential. This becomes pertinent because treatments that are senostatic in vitro (e.g. dietary restriction mimetics) persistently reduce numbers of senescent cells in vivo, i.e. act as net senolytics in immunocompetent hosts.
Collapse
Affiliation(s)
- Susan Short
- Leeds Institute of Cancer and Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Beckett St, Leeds LS9 7TF, UK
| | - Edward Fielder
- Newcastle University Institute for Ageing, Institute for Cell and Molecular Biology, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE4 5PL, UK
| | - Satomi Miwa
- Newcastle University Institute for Ageing, Institute for Cell and Molecular Biology, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE4 5PL, UK
| | - Thomas von Zglinicki
- Newcastle University Institute for Ageing, Institute for Cell and Molecular Biology, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE4 5PL, UK.
| |
Collapse
|
25
|
Samarasekara J, Esteves F, Curd A, Hale M, Magee D, Treanor D, Short S, Brüning-Richardson A. TMOD-13. A NOVEL 3D HIGH-RESOLUTION HISTOPATHOLOGICAL IMAGE RECONSTRUCTION METHOD VERSUS COMMON 2D AND 3D IMAGING METHODOLOGIES FOR APPLICATION IN CANCER SPHEROID RESEARCH: WHICH IS BETTER? Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.1125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | | | - Michael Hale
- University of Leeds, Leeds, England, United Kingdom
| | - Derek Magee
- University of Leeds, Leeds, England, United Kingdom
| | | | - Susan Short
- University of Leeds, Leeds, England, United Kingdom
| | | |
Collapse
|
26
|
Mathew R, da Silva B, Polson E, Williams J, Tams D, O’Shea O, Taylor C, Shaw G, Ballereau S, Short S, Smith C, Rutka J, Chumas P, Markowetz F, Wurdak H. TMOD-24. PATIENT-DERIVED BRAIN TUMOUR IPSCS: MODELS FOR INVESTIGATING GLIOMA STEMNESS AND DRUG DISCOVERY. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.1136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Ryan Mathew
- Leeds General Infirmary, Leeds, England, United Kingdom
| | | | - Euan Polson
- University of Leeds, Leeds, England, United Kingdom
| | | | - Daniel Tams
- Censo Biotechnologies Ltd, Cambridge, England, United Kingdom
| | - Orla O’Shea
- UK Stem Cell Bank (National Institute for Biological Standards and Control), Potters Bar, England, United Kingdom
| | | | - Gary Shaw
- University of Leeds, Leeds, England, United Kingdom
| | - Stephane Ballereau
- Cancer Research UK Cambridge Institute (University of Cambridge), Cambridge, England, United Kingdom
| | - Susan Short
- University of Leeds, Leeds, England, United Kingdom
| | - Christian Smith
- Arthur and Sonia Labatt Brain Tumour Research Centre (The Hospital for Sick Children), Toronto, Ontario, Canada
| | - James Rutka
- Arthur and Sonia Labatt Brain Tumour Research Centre (The Hospital for Sick Children), Toronto, Ontario, Canada
| | - Paul Chumas
- University of Leeds & Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom
| | - Florian Markowetz
- Cancer Research UK Cambridge Institute (University of Cambridge), Cambridge, England, United Kingdom
| | - Heiko Wurdak
- University of Leeds, Leeds, England, United Kingdom
| |
Collapse
|
27
|
Forsyth C, Irving M, Tennant M, Short S, Gilroy J. Indigenous cultural competence: A dental faculty curriculum review. Eur J Dent Educ 2018; 22:e419-e426. [PMID: 29288521 DOI: 10.1111/eje.12320] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/05/2017] [Indexed: 06/07/2023]
Abstract
BACKGROUND Indigenous Australians have more than double the rate of poor oral health than their non-Indigenous counterparts. Cultural competence of dental and oral health practitioners is fundamental to health care and quality of life in addressing health disparities in minority cultural groups in Australia. Higher education curricula reviews have identified the need for institutions to incorporate Indigenous culture and knowledge more widely into the curricula to improve educational outcomes for Indigenous Australians and to increase cultural competence for all students. AIM The aim of this research was to provide a baseline analysis of Indigenous cultural competence curricula practices to ascertain changes required within Faculty of Dentistry programmes at the University of Sydney to enable students to become more culturally competent upon graduation. METHODS Staff and students of the Doctor of Dental Medicine and Bachelor of Oral Health programmes at the Faculty of Dentistry, University of Sydney participated in an online survey. Quantitative analysis of the survey data was conducted using integrated research electronic data capture survey tools, with open-ended questions being coded to common responses for those questions. RESULTS A total of 69 staff (71%) and 191 students (51%) participated in the online survey. The majority of participants perceived there was limited Indigenous content in the curriculum. Most participants reported that Indigenous curriculum was integrated into several units of study. The main pedagogical method for curriculum delivery was lectures, followed by case studies and group discussions. CONCLUSION Although some Indigenous content exists in dental faculty curriculum, in-depth investigation is required to develop a comprehensive, evidenced-based Indigenous cultural competence teaching framework, for integration into Doctor of Dental Medicine and Bachelor of Oral Health curricula.
Collapse
Affiliation(s)
- C Forsyth
- Faculty of Dentistry, The University of Sydney, Westmead, NSW, Australia
| | - M Irving
- Faculty of Dentistry, The University of Sydney, Westmead, NSW, Australia
| | - M Tennant
- International Research Collaborative - Oral Health and Equity, The University of Western Australia, Crawley, WA, Australia
| | - S Short
- Discipline of Behavioural & Social Sciences in Health, Faculty of Health Sciences, WHO Collaborating Centre in Health Workforce Development in Rehabilitation and Long Term Care, The University of Sydney, Lidcombe, NSW, Australia
| | - J Gilroy
- Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia
| |
Collapse
|
28
|
Chalmers AJ, Short S, Watts C, Herbert C, Morris A, Stobo J, Cruickshank G, Dunn L, Erridge S, Godfrey L, Jefferies S, Lopez JS, McBain C, Pittman M, Dillon S, James A, Nowicki SA, Williamson A, Kelly C, Halford SER. Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Colin Watts
- University of Cambridge, Cambridge, United Kingdom
| | | | - Anna Morris
- University of Glasgow, Glasgow, United Kingdom
| | - Jamie Stobo
- Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom
| | - Garth Cruickshank
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Laurence Dunn
- Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom
| | - Sara Erridge
- University of Edinbugh, Edinburgh, United Kingdom
| | - Lisa Godfrey
- Cancer Research UK Centre for Drug Development, London, United Kingdom
| | - Sarah Jefferies
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | | | | | - Marc Pittman
- Cancer Research UK Centre for Drug Development, London, United Kingdom
| | | | - Allan James
- The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | | | | | | | | |
Collapse
|
29
|
Chahal S, Chalmers A, Short S. EP-2328: AT13387 in combination with radiotherapy in clinically relevant models of glioblastoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32637-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
30
|
Wyatt J, Hedley S, Johnstone E, Speight R, Kelly C, Henry A, Short S, Murray L, Sebag-Montefiore D, McCallum H. Evaluating the repeatability and set-up sensitivity of a large field of view distortion phantom and software for magnetic resonance-only radiotherapy. Phys Imaging Radiat Oncol 2018; 6:31-38. [PMID: 33458386 PMCID: PMC7807542 DOI: 10.1016/j.phro.2018.04.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 04/16/2018] [Accepted: 04/18/2018] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND AND PURPOSE Magnetic Resonance (MR)-only radiotherapy requires geometrically accurate MR images over the full scanner Field of View (FoV). This study aimed to investigate the repeatability of distortion measurements made using a commercial large FoV phantom and analysis software and the sensitivity of these measurements to small set-up errors. MATERIALS AND METHODS Geometric distortion was measured using a commercial phantom and software with 2D and 3D acquisition sequences on three different MR scanners. Two sets of repeatability measurements were made: three scans acquired without moving the phantom between scans (single set-up) and five scans acquired with the phantom re-set up in between each scan (repeated set-up). The set-up sensitivity was assessed by scanning the phantom with an intentional 1 mm lateral offset and independently an intentional 1° rotation. RESULTS The mean standard deviation of distortion for all phantom markers for the repeated set-up scans was < 0.4 mm for all scanners and sequences. For the 1 mm lateral offset scan 90 % of the markers agreed within two standard deviations of the mean of the repeated set-up scan (median of all scanners and sequences, range 78%-93%). For the 1° rotation scan, 80% of markers agreed within two standard deviations of the mean (range 69%-93%). CONCLUSIONS Geometric distortion measurements using a commercial phantom and associated software appear repeatable, although with some sensitivity to set-up errors. This suggests the phantom and software are appropriate for commissioning a MR-only radiotherapy workflow.
Collapse
Affiliation(s)
- Jonathan Wyatt
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| | - Stephen Hedley
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| | - Emily Johnstone
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - Richard Speight
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Charles Kelly
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| | - Ann Henry
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Susan Short
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Louise Murray
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
| | - David Sebag-Montefiore
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Hazel McCallum
- Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| |
Collapse
|
31
|
Johnstone E, Wyatt J, Henry A, Broadbent D, Short S, Sebag-Montefiore D, Kelly C, Al-Qaisieh B, Murray L, McCallum H, Speight R. EP-2136: Assessing the stability of MRI geometric distortions on multiple scanners. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32445-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Taylor S, Knipp S, Mavria G, Ladbury J, Brüning-Richardson A, Short S. Finding the brake: dissecting the RhoA pathway regulating glioma cell migration. Neuro Oncol 2018. [DOI: 10.1093/neuonc/nox238.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Egnuni T, Speirs V, Chakrabarty A, Wurdak H, Short S, Mavria G. Rho GTPase signaling and role of the Rac1 exchange factor DOCK4 in GBM invasion and vascular growth. Neuro Oncol 2018. [DOI: 10.1093/neuonc/nox238.077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Egbivwie N, Warr T, Humphries M, Esteves F, Short S, Cockle J, Brüning-Richardson A. A role for FGFR1 in paediatric gliomas. Neuro Oncol 2018. [DOI: 10.1093/neuonc/nox238.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Short S, Hutton B, Ottobrini L, De Francesco I, Fiorini: C. Integrated SPECT-MRI for enhanced stratification and early treatment response assessment in glioma. Neuro Oncol 2018. [DOI: 10.1093/neuonc/nox237.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Rippaus N, Morton R, Taylor C, Bruns AF, Wurdak H, Chakrabarty A, Ismail A, Short S, Stead L. Optimising single cell RNAseq for the analysis of paired primary and recurrent Glioblastoma. Neuro Oncol 2018. [DOI: 10.1093/neuonc/nox238.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Jackman L, Ago E, Boissinot M, Grigg R, Esteves F, Morton R, Short S, Brüning-Richardson A. Tackling infiltration in paediatric glioma using histone deacetylase inhibitors, a promising approach. Neuro Oncol 2018. [DOI: 10.1093/neuonc/nox238.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Droop A, Bruns A, Tanner G, Rippaus N, Morton R, Harrison S, King H, Ashton K, Syed K, Jenkinson MD, Brodbelt A, Chakrabarty A, Ismail A, Short S, Stead LF. How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma. Int J Cancer 2017; 142:1620-1626. [PMID: 29194603 DOI: 10.1002/ijc.31184] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 10/09/2017] [Accepted: 11/15/2017] [Indexed: 12/19/2022]
Abstract
Many traits of cancer progression (e.g., development of metastases or resistance to therapy) are facilitated by tumour evolution: Darwinian selection of subclones with distinct genotypes or phenotypes that enable such progression. Characterising these subclones provide an opportunity to develop drugs to better target their specific properties but requires the accurate identification of somatic mutations shared across multiple spatiotemporal tumours from the same patient. Current best practices for calling somatic mutations are optimised for single samples, and risk being too conservative to identify shared mutations with low prevalence in some samples. We reasoned that datasets from multiple matched tumours can be used for mutual validation and thus propose an adapted two-stage approach: (1) low-stringency mutation calling to identify mutations shared across samples irrespective of the weight of evidence in a single sample; (2) high-stringency mutation calling to further characterise mutations present in a single sample. We applied our approach to three-independent cohorts of paired primary and recurrent glioblastoma tumours, two of which have previously been analysed using existing approaches, and found that it significantly increased the amount of biologically relevant shared somatic mutations identified. We also found that duplicate removal was detrimental when identifying shared somatic mutations. Our approach is also applicable when multiple datasets e.g. DNA and RNA are available for the same tumour.
Collapse
Affiliation(s)
- Alastair Droop
- MRC Medical Bioinformatics Centre, University of Leeds, Leeds, LS2 9NL, United Kingdom
| | - Alexander Bruns
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Georgette Tanner
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Nora Rippaus
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Ruth Morton
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Sally Harrison
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Henry King
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Katherine Ashton
- Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Preston, PR2 9HT, United Kingdom
| | - Khaja Syed
- Walton Centre NHS Trust, Liverpool, L9 7LJ, United Kingdom
| | - Michael D Jenkinson
- Walton Centre NHS Trust, Liverpool, L9 7LJ, United Kingdom.,Institute of Translational Medicine, University of Liverpool, Liverpool, L9 7LJ, United Kingdom
| | | | - Aruna Chakrabarty
- Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, LS9 7TF, United Kingdom
| | - Azzam Ismail
- Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, LS9 7TF, United Kingdom
| | - Susan Short
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| | - Lucy F Stead
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, United Kingdom
| |
Collapse
|
39
|
Abstract
Menstrual health is central to girls' wellbeing, and is connected to their rights to health, education, safety, non-discrimination, and autonomy. This article investigates girls' experiences of menstruation in present-day Ethiopia. Results, based on data collected from 120 girls in two regions, illustrate the challenges associated with menstruation, including menstrual taboos and cultural beliefs surrounding menstruation, myths about menstruation and sex, and restrictive social expectations related to marriage, and interpersonal interaction. These challenges diminish girls' health, education, safety, and autonomy, and in so doing, underscore the relevance of menstrual health to rights' agendas that seek to advance girls' wellbeing.
Collapse
Affiliation(s)
| | | | - Marni Sommer
- Columbia University Mailman School of Public Health
| |
Collapse
|
40
|
Cockle JV, Brüning-Richardson A, Scott KJ, Thompson J, Kottke T, Morrison E, Ismail A, Carcaboso AM, Rose A, Selby P, Conner J, Picton S, Short S, Vile R, Melcher A, Ilett E. Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Mol Ther Oncolytics 2017; 5:75-86. [PMID: 28547002 PMCID: PMC5435599 DOI: 10.1016/j.omto.2017.04.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2017] [Accepted: 04/25/2017] [Indexed: 12/13/2022] Open
Abstract
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumors with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via immune-mediated mechanisms. Here we investigate a previously unreported mechanism of action: the inhibition of migration and invasion in pediatric brain tumors. We evaluated the effect of oncolytic herpes simplex virus 1716 (HSV1716) on the migration and invasion of pHGG and DIPG both in vitro using 2D (scratch assay, live cell imaging) and 3D (spheroid invasion in collagen) assays and in vivo using an orthotopic xenograft model of DIPG invasion. HSV1716 inhibited migration and invasion in pHGG and DIPG cell lines. pHGG cells demonstrated reduced velocity and changed morphology in the presence of virus. HSV1716 altered pHGG cytoskeletal dynamics by stabilizing microtubules, inhibiting glycogen synthase kinase-3, and preventing localized clustering of adenomatous polyposis coli (APC) to the leading edge of cells. HSV1716 treatment also reduced tumor infiltration in a mouse orthotopic xenograft DIPG model. Our results demonstrate that HSV1716 targets the migration and invasion of pHGG and DIPG and indicates the potential of an oncolytic virus (OV) to be used as a novel anti-invasive treatment strategy for pediatric brain tumors.
Collapse
Affiliation(s)
- Julia V. Cockle
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
- Yorkshire Regional Centre for Paediatric Oncology and Haematology, Leeds General Infirmary, Leeds LS1 3EX, UK
| | | | - Karen J. Scott
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
| | - Jill Thompson
- Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
| | - Timothy Kottke
- Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
| | - Ewan Morrison
- Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds LS9 7TF, UK
| | - Azam Ismail
- Department of Pathology, St. James’s University Hospital, Leeds LS9 7TF, UK
| | | | - Ailsa Rose
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
| | - Peter Selby
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
| | | | - Susan Picton
- Yorkshire Regional Centre for Paediatric Oncology and Haematology, Leeds General Infirmary, Leeds LS1 3EX, UK
| | - Susan Short
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
| | - Richard Vile
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
- Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
| | - Alan Melcher
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
- Institute of Cancer Research, London SM2 5NG, UK
| | - Elizabeth Ilett
- Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
| |
Collapse
|
41
|
Twelves C, Short S, Wright S. A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.2046] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2046 Background: Several plant-derived cannabinoids have shown efficacy in animal models of GBM, particularly when co-administered with temozolomide, a commonly-used treatment in both primary and recurrent disease. Methods: We conducted a two-part study in patients with recurrent GBM following standard chemo-radiotherapy treatment as described by Stupp et al. In Part 1 of the study, 6 patients were treated to an MTD of 1:1 CBD:THC oro-mucosal spray, as an adjunct to dose-intense temozolomide (DIT), to assess the safety of the combination. Part 2 was a double blind, randomized, placebo-controlled study in a planned 20 patients receiving either their individualized dose of 1:1 CBD:THC or placebo plus DIT. The primary endpoint was tolerability of 1:1 CBD:THC plus temozolomide. Results: There were no Grade 3 or 4 toxicities in Part 1 of the study. In Part 2, 12 patients were randomized to CBD:THC and 9 to placebo. Mean age was 58 years in both treatment groups, but there were more males in the placebo group (5 of 12 and 8 of 9, respectively). Baseline median Karnofsky score was 90 in both groups and median time from diagnosis of recurrence to start of treatment (day 1) was similar (3.6 and 3.0 weeks in the CBD:THC and placebo group, respectively). The median number of days of dosing with CBD:THC or placebo was similar (155 days [range: 50-356] and 134 days [range: 13-359]). Median survival in the placebo group was 369 days, and > 550 days in the CBD:THC treatment group (NS) and 1 year survival was 83% and 56% in the CBD:THC and placebo groups, respectively (p = 0.042). PFS6 was 42% in the CBD:THC group and 33% in the placebo group (NS). Overall, the commonest treatment related toxicities were dizziness (in 11/18 patients) and nausea (in 7/18 patients). Results of biomarker analyses are awaited. Conclusions: This randomized study provides preliminary evidence that 1:1 CBD:THC offers some efficacy in patients with recurrent GBM when used as an adjunct to dose-intense temozolomide and confirms the safety and feasibility of individualized dosing. Clinical trial information: NCT01812603.
Collapse
Affiliation(s)
- Chris Twelves
- University of Leeds and St. James's Institute of Oncology, Leeds, United Kingdom
| | | | | | | |
Collapse
|
42
|
Wyatt J, Hedley S, Johnstone E, Speight R, Kelly C, Henry A, Short S, Murray L, Sebag-Montefiore D, McCallum H. EP-1708: Investigating the reproducibility of geometric distortion measurements for MR-only radiotherapy. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32240-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
43
|
Maclean J, Fersht N, Sullivan K, Kayani I, Bomanji J, Dickson J, O'Meara C, Short S. Simultaneous 68Ga DOTATATE Positron Emission Tomography/Magnetic Resonance Imaging in Meningioma Target Contouring: Feasibility and Impact Upon Interobserver Variability Versus Positron Emission Tomography/Computed Tomography and Computed Tomography/Magnetic Resonance Imaging. Clin Oncol (R Coll Radiol) 2017; 29:448-458. [PMID: 28433399 DOI: 10.1016/j.clon.2017.03.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 02/16/2017] [Accepted: 02/21/2017] [Indexed: 10/19/2022]
Abstract
AIMS The increasing use of highly conformal radiation techniques to treat meningioma confers a greater need for accurate targeting. Several groups have shown that positron emission tomography/computed tomography (PET/CT) information alters meningioma targets contoured by single observers, but whether this translates into improved accuracy has not been defined. As magnetic resonance imaging (MRI) is the cornerstone of meningioma target contouring, simultaneous PET/MRI may be superior to PET/CT. We assessed whether 68Ga DOTATATE PET imaging (from PET/CT and PET/MRI) reduced interobserver variability (IOV) in meningioma target volume contouring. MATERIALS AND METHODS Ten patients with meningioma underwent simultaneous 68Ga DOTATATE PET/MRI followed by PET/CT. They were selected as it was anticipated that target volume definition in their cases would be particularly challenging. Three radiation oncologists contoured target volumes according to an agreed protocol: gross tumour volume (GTV) and clinical target volume (CTV) on CT/MRI alone, CT/MRI+PET(CT) and CT/MRI+PET(MRI). GTV/CTV Kouwenhoven conformity levels (KCL), regions of contour variation and qualitative differences between PET(CT) and PET(MRI) were evaluated. RESULTS There was substantial IOV in contouring. GTV mean KCL: CT/MRI 0.34, CT/MRI+PET(CT) 0.38, CT/MRI+PET(MRI) 0.39 (P = 0.06). CTV mean KCL: CT/MRI 0.31, CT/MRI+PET(CT) 0.35, CT/MRI+PET(MRI) 0.35 (P = 0.04 for all groups; P > 0.05 for individual pairs). One observer consistently contoured largest and one smallest. Observers rarely decreased volumes in relation to PET. Most IOV occurred in bone followed by dural tail, postoperative bed and venous sinuses. Tumour edges were qualitatively clearer on PET(MRI) versus PET(CT), but this did not affect contouring. CONCLUSION IOV in contouring challenging meningioma cases was large and only slightly improved with the addition of 68Ga DOTATATE PET. Simultaneous PET/MRI for meningioma contouring is feasible, but did not improve IOV versus PET/CT. Whether volumes can be safely reduced according to PET requires evaluation.
Collapse
Affiliation(s)
- J Maclean
- University College London Hospitals NHS Trust, London, UK.
| | - N Fersht
- University College London Hospitals NHS Trust, London, UK
| | - K Sullivan
- University College London Hospitals NHS Trust, London, UK
| | - I Kayani
- University College London Hospitals NHS Trust, London, UK
| | - J Bomanji
- University College London Hospitals NHS Trust, London, UK
| | - J Dickson
- University College London Hospitals NHS Trust, London, UK
| | - C O'Meara
- University College London Hospitals NHS Trust, London, UK
| | - S Short
- University College London Hospitals NHS Trust, London, UK
| |
Collapse
|
44
|
Abe K, Amey J, Andreopoulos C, Antonova M, Aoki S, Ariga A, Autiero D, Ban S, Barbi M, Barker GJ, Barr G, Barry C, Bartet-Friburg P, Batkiewicz M, Berardi V, Berkman S, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bordoni S, Boyd SB, Brailsford D, Bravar A, Bronner C, Buizza Avanzini M, Calland RG, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Checchia C, Cherdack D, Chikuma N, Christodoulou G, Clifton A, Coleman J, Collazuol G, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Dewhurst D, Di Lodovico F, Di Luise S, Dolan S, Drapier O, Duffy KE, Dumarchez J, Dziewiecki M, Emery-Schrenk S, Ereditato A, Feusels T, Finch AJ, Fiorentini GA, Friend M, Fujii Y, Fukuda D, Fukuda Y, Galymov V, Garcia A, Giganti C, Gizzarelli F, Golan T, Gonin M, Hadley DR, Haegel L, Haigh MD, Hansen D, Harada J, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Helmer RL, Hillairet A, Hiraki T, Hiramoto A, Hirota S, Hogan M, Holeczek J, Hosomi F, Huang K, Ichikawa AK, Ikeda M, Imber J, Insler J, Intonti RA, Ishida T, Ishii T, Iwai E, Iwamoto K, Izmaylov A, Jamieson B, Jiang M, Johnson S, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Katori T, Kearns E, Khabibullin M, Khotjantsev A, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kondo K, Kormos LL, Korzenev A, Koshio Y, Kowalik K, Kropp W, Kudenko Y, Kurjata R, Kutter T, Lagoda J, Lamont I, Lamoureux M, Larkin E, Lasorak P, Laveder M, Lawe M, Licciardi M, Lindner T, Liptak ZJ, Litchfield RP, Li X, Longhin A, Lopez JP, Lou T, Ludovici L, Lu X, Magaletti L, Mahn K, Malek M, Manly S, Marino AD, Martin JF, Martins P, Martynenko S, Maruyama T, Matveev V, Mavrokoridis K, Ma WY, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Mijakowski P, Minamino A, Mineev O, Mine S, Missert A, Miura M, Moriyama S, Mueller TA, Myslik J, Nakadaira T, Nakahata M, Nakamura KG, Nakamura K, Nakamura KD, Nakanishi Y, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Nielsen C, Nirkko M, Nishikawa K, Nishimura Y, Novella P, Nowak J, O'Keeffe HM, Okumura K, Okusawa T, Oryszczak W, Oser SM, Ovsyannikova T, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Patel ND, Paudyal P, Pavin M, Payne D, Perkin JD, Petrov Y, Pickard L, Pickering L, Pinzon Guerra ES, Pistillo C, Popov B, Posiadala-Zezula M, Poutissou JM, Poutissou R, Przewlocki P, Quilain B, Radermacher T, Radicioni E, Ratoff PN, Ravonel M, Rayner MA, Redij A, Reinherz-Aronis E, Riccio C, Rodrigues PA, Rondio E, Rossi B, Roth S, Rubbia A, Rychter A, Sakashita K, Sánchez F, Scantamburlo E, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaw D, Shiozawa M, Shirahige T, Short S, Smy M, Sobczyk JT, Sobel H, Sorel M, Southwell L, Steinmann J, Stewart T, Stowell P, Suda Y, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Tacik R, Tada M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Terhorst D, Terri R, Thakore T, Thompson LF, Tobayama S, Toki W, Tomura T, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Vagins M, Vallari Z, Vasseur G, Vladisavljevic T, Wachala T, Walter CW, Wark D, Wascko MO, Weber A, Wendell R, Wilkes RJ, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wret C, Yamada Y, Yamamoto K, Yamamoto M, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Yoshida K, Yuan T, Yu M, Zalewska A, Zalipska J, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. Combined Analysis of Neutrino and Antineutrino Oscillations at T2K. Phys Rev Lett 2017; 118:151801. [PMID: 28452532 DOI: 10.1103/physrevlett.118.151801] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Indexed: 06/07/2023]
Abstract
T2K reports its first results in the search for CP violation in neutrino oscillations using appearance and disappearance channels for neutrino- and antineutrino-mode beams. The data include all runs from January 2010 to May 2016 and comprise 7.482×10^{20} protons on target in neutrino mode, which yielded in the far detector 32 e-like and 135 μ-like events, and 7.471×10^{20} protons on target in antineutrino mode, which yielded 4 e-like and 66 μ-like events. Reactor measurements of sin^{2}2θ_{13} have been used as an additional constraint. The one-dimensional confidence interval at 90% for the phase δ_{CP} spans the range (-3.13, -0.39) for normal mass ordering. The CP conservation hypothesis (δ_{CP}=0, π) is excluded at 90% C.L.
Collapse
Affiliation(s)
- K Abe
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - J Amey
- Department of Physics, Imperial College London, London, United Kingdom
| | - C Andreopoulos
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - M Antonova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - D Autiero
- Université de Lyon, Université Claude Bernard Lyon 1, IPN Lyon (IN2P3), Villeurbanne, France
| | - S Ban
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Barbi
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
| | - G J Barker
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - G Barr
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - C Barry
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - P Bartet-Friburg
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), UPMC, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - M Batkiewicz
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - V Berardi
- INFN Sezione di Bari and Dipartimento Interuniversitario di Fisica, Università e Politecnico di Bari, Bari, Italy
| | - S Berkman
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - S Bhadra
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - S Bienstock
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), UPMC, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - A Blondel
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | | | - S Bordoni
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - S B Boyd
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - D Brailsford
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - A Bravar
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - C Bronner
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Buizza Avanzini
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - R G Calland
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - T Campbell
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - S Cao
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - S L Cartwright
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - M G Catanesi
- INFN Sezione di Bari and Dipartimento Interuniversitario di Fisica, Università e Politecnico di Bari, Bari, Italy
| | - A Cervera
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - C Checchia
- INFN Sezione di Padova and Dipartimento di Fisica, Università di Padova, Padova, Italy
| | - D Cherdack
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - N Chikuma
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - G Christodoulou
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - A Clifton
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - J Coleman
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - G Collazuol
- INFN Sezione di Padova and Dipartimento di Fisica, Università di Padova, Padova, Italy
| | - D Coplowe
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - A Cudd
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - A Dabrowska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - G De Rosa
- INFN Sezione di Napoli and Dipartimento di Fisica, Università di Napoli, Napoli, Italy
| | - T Dealtry
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - P F Denner
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - S R Dennis
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - C Densham
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - D Dewhurst
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - F Di Lodovico
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - S Di Luise
- Institute for Particle Physics, ETH Zurich, Zurich, Switzerland
| | - S Dolan
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - O Drapier
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - K E Duffy
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - J Dumarchez
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), UPMC, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - M Dziewiecki
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | | | - A Ereditato
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - T Feusels
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - A J Finch
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - G A Fiorentini
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - M Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - D Fukuda
- Department of Physics, Okayama University, Okayama, Japan
| | - Y Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Japan
| | - V Galymov
- Université de Lyon, Université Claude Bernard Lyon 1, IPN Lyon (IN2P3), Villeurbanne, France
| | - A Garcia
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - C Giganti
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), UPMC, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - T Golan
- Faculty of Physics and Astronomy, Wroclaw University, Wroclaw, Poland
| | - M Gonin
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - D R Hadley
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - L Haegel
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - M D Haigh
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - D Hansen
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - J Harada
- Department of Physics, Osaka City University, Osaka, Japan
| | - M Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - N C Hastings
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
| | - T Hayashino
- Department of Physics, Kyoto University, Kyoto, Japan
| | - Y Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - R L Helmer
- TRIUMF, Vancouver, British Columbia, Canada
| | - A Hillairet
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia, Canada
| | - T Hiraki
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A Hiramoto
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Hirota
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Hogan
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - J Holeczek
- Institute of Physics, University of Silesia, Katowice, Poland
| | - F Hosomi
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - K Huang
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A K Ichikawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Ikeda
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - J Imber
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Insler
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - R A Intonti
- INFN Sezione di Bari and Dipartimento Interuniversitario di Fisica, Università e Politecnico di Bari, Bari, Italy
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - E Iwai
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Iwamoto
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - A Izmaylov
- IFIC (CSIC and University of Valencia), Valencia, Spain
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B Jamieson
- Department of Physics, University of Winnipeg, Winnipeg, Manitoba, Canada
| | - M Jiang
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Johnson
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - P Jonsson
- Department of Physics, Imperial College London, London, United Kingdom
| | - C K Jung
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - M Kabirnezhad
- National Centre for Nuclear Research, Warsaw, Poland
| | - A C Kaboth
- Department of Physics, Royal Holloway University of London, Egham, Surrey, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - T Kajita
- Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, University of Tokyo, Kashiwa, Japan
| | - H Kakuno
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - J Kameda
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - D Karlen
- TRIUMF, Vancouver, British Columbia, Canada
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia, Canada
| | - T Katori
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - E Kearns
- Department of Physics, Boston University, Boston, Massachusetts, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - H Kim
- Department of Physics, Osaka City University, Osaka, Japan
| | - J Kim
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - S King
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - J Kisiel
- Institute of Physics, University of Silesia, Katowice, Poland
| | - A Knight
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - A Knox
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - L Koch
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - T Koga
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A Konaka
- TRIUMF, Vancouver, British Columbia, Canada
| | - K Kondo
- Department of Physics, Kyoto University, Kyoto, Japan
| | - L L Kormos
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - A Korzenev
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - Y Koshio
- Department of Physics, Okayama University, Okayama, Japan
| | - K Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - W Kropp
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - R Kurjata
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - T Kutter
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - J Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - I Lamont
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | | | - E Larkin
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - P Lasorak
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - M Laveder
- INFN Sezione di Padova and Dipartimento di Fisica, Università di Padova, Padova, Italy
| | - M Lawe
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - M Licciardi
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - T Lindner
- TRIUMF, Vancouver, British Columbia, Canada
| | - Z J Liptak
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - R P Litchfield
- Department of Physics, Imperial College London, London, United Kingdom
| | - X Li
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - A Longhin
- INFN Sezione di Padova and Dipartimento di Fisica, Università di Padova, Padova, Italy
| | - J P Lopez
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - T Lou
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - L Ludovici
- INFN Sezione di Roma and Università di Roma "La Sapienza," Roma, Italy
| | - X Lu
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - L Magaletti
- INFN Sezione di Bari and Dipartimento Interuniversitario di Fisica, Università e Politecnico di Bari, Bari, Italy
| | - K Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - M Malek
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - S Manly
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - A D Marino
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - J F Martin
- Department of Physics, University of Toronto, Toronto, Ontario, Canada
| | - P Martins
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - S Martynenko
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - T Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Mavrokoridis
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - W Y Ma
- Department of Physics, Imperial College London, London, United Kingdom
| | | | - M McCarthy
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - N McCauley
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - K S McFarland
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - C McGrew
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - A Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Metelko
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - M Mezzetto
- INFN Sezione di Padova and Dipartimento di Fisica, Università di Padova, Padova, Italy
| | - P Mijakowski
- National Centre for Nuclear Research, Warsaw, Poland
| | - A Minamino
- Faculty of Engineering, Yokohama National University, Yokohama, Japan
| | - O Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
| | - A Missert
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - M Miura
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - S Moriyama
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - Th A Mueller
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Myslik
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia, Canada
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - K G Nakamura
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - K D Nakamura
- Department of Physics, Kyoto University, Kyoto, Japan
| | - Y Nakanishi
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Nakayama
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - T Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - C Nantais
- Department of Physics, University of Toronto, Toronto, Ontario, Canada
| | - C Nielsen
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - M Nirkko
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Nishimura
- Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, University of Tokyo, Kashiwa, Japan
| | - P Novella
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - J Nowak
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - H M O'Keeffe
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - K Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, University of Tokyo, Kashiwa, Japan
| | - T Okusawa
- Department of Physics, Osaka City University, Osaka, Japan
| | - W Oryszczak
- Faculty of Physics, University of Warsaw, Warsaw, Poland
| | - S M Oser
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Ovsyannikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - R A Owen
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Palladino
- INFN Sezione di Napoli and Dipartimento di Fisica, Università di Napoli, Napoli, Italy
| | - J L Palomino
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - V Paolone
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - N D Patel
- Department of Physics, Kyoto University, Kyoto, Japan
| | - P Paudyal
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - M Pavin
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), UPMC, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - D Payne
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - J D Perkin
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - Y Petrov
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - L Pickard
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - L Pickering
- Department of Physics, Imperial College London, London, United Kingdom
| | - E S Pinzon Guerra
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - C Pistillo
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - B Popov
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), UPMC, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | | | | | - P Przewlocki
- National Centre for Nuclear Research, Warsaw, Poland
| | - B Quilain
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T Radermacher
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - E Radicioni
- INFN Sezione di Bari and Dipartimento Interuniversitario di Fisica, Università e Politecnico di Bari, Bari, Italy
| | - P N Ratoff
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - M Ravonel
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - M A Rayner
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - A Redij
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - E Reinherz-Aronis
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - C Riccio
- INFN Sezione di Napoli and Dipartimento di Fisica, Università di Napoli, Napoli, Italy
| | - P A Rodrigues
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - E Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - B Rossi
- INFN Sezione di Napoli and Dipartimento di Fisica, Università di Napoli, Napoli, Italy
| | - S Roth
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - A Rubbia
- Institute for Particle Physics, ETH Zurich, Zurich, Switzerland
| | - A Rychter
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - F Sánchez
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - E Scantamburlo
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina, USA
| | - J Schwehr
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - M Scott
- TRIUMF, Vancouver, British Columbia, Canada
| | - Y Seiya
- Department of Physics, Osaka City University, Osaka, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - H Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - D Sgalaberna
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - R Shah
- Department of Physics, Oxford University, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - A Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Shaker
- Department of Physics, University of Winnipeg, Winnipeg, Manitoba, Canada
| | - D Shaw
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - M Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - T Shirahige
- Department of Physics, Okayama University, Okayama, Japan
| | - S Short
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - M Smy
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
| | - J T Sobczyk
- Faculty of Physics and Astronomy, Wroclaw University, Wroclaw, Poland
| | - H Sobel
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Sorel
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - L Southwell
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - J Steinmann
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - T Stewart
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - P Stowell
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - Y Suda
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - S Suvorov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - S Y Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - R Tacik
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - M Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - A Takeda
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - Y Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kobe University, Kobe, Japan
| | - H K Tanaka
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - H A Tanaka
- Department of Physics, University of Toronto, Toronto, Ontario, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - D Terhorst
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - R Terri
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - T Thakore
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - L F Thompson
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - S Tobayama
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - W Toki
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - T Tomura
- Institute for Cosmic Ray Research, Kamioka Observatory, University of Tokyo, Kamioka, Japan
| | - C Touramanis
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tzanov
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Y Uchida
- Department of Physics, Imperial College London, London, United Kingdom
| | - M Vagins
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - Z Vallari
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - G Vasseur
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - T Vladisavljevic
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - T Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - C W Walter
- Department of Physics, Duke University, Durham, North Carolina, USA
| | - D Wark
- Department of Physics, Oxford University, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - M O Wascko
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Department of Physics, Imperial College London, London, United Kingdom
| | - A Weber
- Department of Physics, Oxford University, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, United Kingdom and Daresbury Laboratory, Warrington, United Kingdom
| | - R Wendell
- Department of Physics, Kyoto University, Kyoto, Japan
| | - R J Wilkes
- Department of Physics, University of Washington, Seattle, Washington, USA
| | - M J Wilking
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - C Wilkinson
- Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), University of Bern, Bern, Switzerland
| | - J R Wilson
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - R J Wilson
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - C Wret
- Department of Physics, Imperial College London, London, United Kingdom
| | - Y Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Yamamoto
- Department of Physics, Osaka City University, Osaka, Japan
| | - M Yamamoto
- Department of Physics, Kyoto University, Kyoto, Japan
| | - C Yanagisawa
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - T Yano
- Kobe University, Kobe, Japan
| | - S Yen
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Yokoyama
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - K Yoshida
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T Yuan
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - M Yu
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - A Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - L Zambelli
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Zaremba
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - M Ziembicki
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - E D Zimmerman
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - M Zito
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - J Żmuda
- Faculty of Physics and Astronomy, Wroclaw University, Wroclaw, Poland
| |
Collapse
|
45
|
Samson A, Scott K, Taggart D, West E, Wilson E, Nuovo G, Thomson S, Stead L, Short S, Melcher A. P07.05 Intravenous delivery of oncolytic reovirus to brain tumours in patients to immunologically prime for sequential checkpoint blockade. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Egnuni T, Short S. P01.10 Dock4 heterozygous deletion normalizes the glioblastoma microenvironment & improves response to radiation. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Guillotin D, Austin P, Begum R, Freitas MO, Merve A, Brend T, Short S, Marino S, Martin SA. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells. Clin Cancer Res 2016; 23:2880-2890. [PMID: 27913567 DOI: 10.1158/1078-0432.ccr-16-1216] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 11/17/2016] [Accepted: 11/21/2016] [Indexed: 11/16/2022]
Abstract
Purpose: The DNA mismatch repair (MMR) pathway is required for the maintenance of genome stability. Unsurprisingly, mutations in MMR genes occur in a wide range of different cancers. Studies thus far have largely focused on specific tumor types or MMR mutations; however, it is becoming increasingly clear that a therapy targeting MMR deficiency in general would be clinically very beneficial.Experimental Design: Based on a drug-repositioning approach, we screened a large panel of cell lines with various MMR deficiencies from a range of different tumor types with a compound drug library of previously approved drugs. We have identified the potassium-sparing diuretic drug triamterene, as a novel sensitizing agent in MMR-deficient tumor cells, in vitro and in vivoResults: The selective tumor cell cytotoxicity of triamterene occurs through its antifolate activity and depends on the activity of the folate synthesis enzyme thymidylate synthase. Triamterene leads to a thymidylate synthase-dependent differential increase in reactive oxygen species in MMR-deficient cells, ultimately resulting in an increase in DNA double-strand breaks.Conclusions: Conclusively, our data reveal a new drug repurposing and novel therapeutic strategy that has potential for the treatment of MMR deficiency in a range of different tumor types and could significantly improve patient survival. Clin Cancer Res; 23(11); 2880-90. ©2016 AACR.
Collapse
Affiliation(s)
- Delphine Guillotin
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Philip Austin
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Rumena Begum
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Marta O Freitas
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Ashirwad Merve
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London, E1 2AT, UK
| | - Tim Brend
- Leeds Institute of Cancer and Pathology, Wellcome Trust Brenner Building St James's University Hospital, Beckett St, Leeds, LS9 7TF, UK
| | - Susan Short
- Leeds Institute of Cancer and Pathology, Wellcome Trust Brenner Building St James's University Hospital, Beckett St, Leeds, LS9 7TF, UK
| | - Silvia Marino
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London, E1 2AT, UK
| | - Sarah A Martin
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| |
Collapse
|
48
|
Reed MJ, Gibson L, Black P, Dewar A, Clegg G, Short S. THE PARAMEDIC ULTRASOUND IN CARDIAC ARREST STUDY. Arch Emerg Med 2016. [DOI: 10.1136/emermed-2016-206402.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Abe K, Andreopoulos C, Antonova M, Aoki S, Ariga A, Assylbekov S, Autiero D, Ban S, Barbi M, Barker GJ, Barr G, Bartet-Friburg P, Batkiewicz M, Bay F, Berardi V, Berkman S, Bhadra S, Blondel A, Bolognesi S, Bordoni S, Boyd SB, Brailsford D, Bravar A, Bronner C, Buizza Avanzini M, Calland RG, Campbell T, Cao S, Caravaca Rodríguez J, Cartwright SL, Castillo R, Catanesi MG, Cervera A, Cherdack D, Chikuma N, Christodoulou G, Clifton A, Coleman J, Collazuol G, Coplowe D, Cremonesi L, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Dewhurst D, Di Lodovico F, Di Luise S, Dolan S, Drapier O, Duffy KE, Dumarchez J, Dytman S, Dziewiecki M, Emery-Schrenk S, Ereditato A, Feusels T, Finch AJ, Fiorentini GA, Friend M, Fujii Y, Fukuda D, Fukuda Y, Furmanski AP, Galymov V, Garcia A, Giffin SG, Giganti C, Gizzarelli F, Gonin M, Grant N, Hadley DR, Haegel L, Haigh MD, Hamilton P, Hansen D, Harada J, Hara T, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Helmer RL, Hierholzer M, Hillairet A, Himmel A, Hiraki T, Hirota S, Hogan M, Holeczek J, Horikawa S, Hosomi F, Huang K, Ichikawa AK, Ieki K, Ikeda M, Imber J, Insler J, Intonti RA, Irvine TJ, Ishida T, Ishii T, Iwai E, Iwamoto K, Izmaylov A, Jacob A, Jamieson B, Jiang M, Johnson S, Jo JH, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Karpikov I, Katori T, Kearns E, Khabibullin M, Khotjantsev A, Kielczewska D, Kikawa T, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kondo K, Kopylov A, Kormos LL, Korzenev A, Koshio Y, Kropp W, Kudenko Y, Kurjata R, Kutter T, Lagoda J, Lamont I, Larkin E, Lasorak P, Laveder M, Lawe M, Lazos M, Lindner T, Liptak ZJ, Litchfield RP, Li X, Longhin A, Lopez JP, Ludovici L, Lu X, Magaletti L, Mahn K, Malek M, Manly S, Marino AD, Marteau J, Martin JF, Martins P, Martynenko S, Maruyama T, Matveev V, Mavrokoridis K, Ma WY, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Mijakowski P, Minamino A, Mineev O, Mine S, Missert A, Miura M, Moriyama S, Mueller TA, Murphy S, Myslik J, Nakadaira T, Nakahata M, Nakamura KG, Nakamura K, Nakamura KD, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Nielsen C, Nirkko M, Nishikawa K, Nishimura Y, Novella P, Nowak J, O'Keeffe HM, Ohta R, Okumura K, Okusawa T, Oryszczak W, Oser SM, Ovsyannikova T, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Patel ND, Pavin M, Payne D, Perkin JD, Petrov Y, Pickard L, Pickering L, Pinzon Guerra ES, Pistillo C, Popov B, Posiadala-Zezula M, Poutissou JM, Poutissou R, Przewlocki P, Quilain B, Radermacher T, Radicioni E, Ratoff PN, Ravonel M, Rayner MAM, Redij A, Reinherz-Aronis E, Riccio C, Rojas P, Rondio E, Roth S, Rubbia A, Rychter A, Sacco R, Sakashita K, Sánchez F, Sato F, Scantamburlo E, Scholberg K, Schoppmann S, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaw D, Shiozawa M, Shirahige T, Short S, Smy M, Sobczyk JT, Sobel H, Sorel M, Southwell L, Stamoulis P, Steinmann J, Stewart T, Stowell P, Suda Y, Suvorov S, Suzuki A, Suzuki K, Suzuki SY, Suzuki Y, Tacik R, Tada M, Takahashi S, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Terhorst D, Terri R, Thakore T, Thompson LF, Tobayama S, Toki W, Tomura T, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Vacheret A, Vagins M, Vallari Z, Vasseur G, Wachala T, Wakamatsu K, Walter CW, Wark D, Warzycha W, Wascko MO, Weber A, Wendell R, Wilkes RJ, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Yamada Y, Yamamoto K, Yamamoto M, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Yoo J, Yoshida K, Yuan T, Yu M, Zalewska A, Zalipska J, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. Measurement of Coherent π^{+} Production in Low Energy Neutrino-Carbon Scattering. Phys Rev Lett 2016; 117:192501. [PMID: 27858422 DOI: 10.1103/physrevlett.117.192501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Indexed: 06/06/2023]
Abstract
We report the first measurement of the flux-averaged cross section for charged current coherent π^{+} production on carbon for neutrino energies less than 1.5 GeV, and with a restriction on the final state phase space volume in the T2K near detector, ND280. Comparisons are made with predictions from the Rein-Sehgal coherent production model and the model by Alvarez-Ruso et al., the latter representing the first implementation of an instance of the new class of microscopic coherent models in a neutrino interaction Monte Carlo event generator. We observe a clear event excess above background, disagreeing with the null results reported by K2K and SciBooNE in a similar neutrino energy region. The measured flux-averaged cross sections are below those predicted by both the Rein-Sehgal and Alvarez-Ruso et al.
Collapse
Affiliation(s)
- K Abe
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - C Andreopoulos
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - M Antonova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - S Assylbekov
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - D Autiero
- Université de Lyon, Université Claude Bernard Lyon 1, IPN Lyon (IN2P3), Villeurbanne, France
| | - S Ban
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Barbi
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
| | - G J Barker
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - G Barr
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - P Bartet-Friburg
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - M Batkiewicz
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - F Bay
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - V Berardi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - S Berkman
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - S Bhadra
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - A Blondel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | | | - S Bordoni
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - S B Boyd
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - D Brailsford
- Department of Physics, Imperial College London, London, United Kingdom
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - A Bravar
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - C Bronner
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Buizza Avanzini
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - R G Calland
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - T Campbell
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - S Cao
- Department of Physics, Kyoto University, Kyoto, Japan
| | - J Caravaca Rodríguez
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - S L Cartwright
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - R Castillo
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - M G Catanesi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - A Cervera
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - D Cherdack
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - N Chikuma
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - G Christodoulou
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - A Clifton
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - J Coleman
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - G Collazuol
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padova, Italy
| | - D Coplowe
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - L Cremonesi
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - A Dabrowska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - G De Rosa
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Napoli, Italy
| | - T Dealtry
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - P F Denner
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - S R Dennis
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - C Densham
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - D Dewhurst
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - F Di Lodovico
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - S Di Luise
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - S Dolan
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - O Drapier
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - K E Duffy
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - J Dumarchez
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - S Dytman
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - M Dziewiecki
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | | | - A Ereditato
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - T Feusels
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - A J Finch
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - G A Fiorentini
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - M Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - D Fukuda
- Department of Physics, Okayama University, Okayama, Japan
| | - Y Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Japan
| | - A P Furmanski
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - V Galymov
- Université de Lyon, Université Claude Bernard Lyon 1, IPN Lyon (IN2P3), Villeurbanne, France
| | - A Garcia
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - S G Giffin
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
| | - C Giganti
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | | | - M Gonin
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - N Grant
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - D R Hadley
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - L Haegel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - M D Haigh
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - P Hamilton
- Department of Physics, Imperial College London, London, United Kingdom
| | - D Hansen
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - J Harada
- Department of Physics, Osaka City University, Osaka, Japan
| | - T Hara
- Kobe University, Kobe, Japan
| | - M Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - N C Hastings
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
| | - T Hayashino
- Department of Physics, Kyoto University, Kyoto, Japan
| | - Y Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - R L Helmer
- TRIUMF, Vancouver, British Columbia, Canada
| | - M Hierholzer
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - A Hillairet
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia, Canada
| | - A Himmel
- Department of Physics, Duke University, Durham, North Carolina, USA
| | - T Hiraki
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Hirota
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Hogan
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - J Holeczek
- Institute of Physics, University of Silesia, Katowice, Poland
| | - S Horikawa
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - F Hosomi
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - K Huang
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A K Ichikawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K Ieki
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Ikeda
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - J Imber
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Insler
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - R A Intonti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - T J Irvine
- Institute for Cosmic Ray Research, University of Tokyo, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - E Iwai
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Iwamoto
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - A Izmaylov
- IFIC (CSIC & University of Valencia), Valencia, Spain
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Jacob
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - B Jamieson
- Department of Physics, University of Winnipeg, Winnipeg, Manitoba, Canada
| | - M Jiang
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Johnson
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - J H Jo
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - P Jonsson
- Department of Physics, Imperial College London, London, United Kingdom
| | - C K Jung
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - M Kabirnezhad
- National Centre for Nuclear Research, Warsaw, Poland
| | - A C Kaboth
- Department of Physics, Royal Holloway University of London, Egham, Surrey, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - T Kajita
- Institute for Cosmic Ray Research, University of Tokyo, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - H Kakuno
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - J Kameda
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - D Karlen
- TRIUMF, Vancouver, British Columbia, Canada
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia, Canada
| | - I Karpikov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Katori
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - E Kearns
- Department of Physics, Boston University, Boston, Massachusetts, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - D Kielczewska
- Faculty of Physics, University of Warsaw, Warsaw, Poland
| | - T Kikawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - H Kim
- Department of Physics, Osaka City University, Osaka, Japan
| | - J Kim
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - S King
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - J Kisiel
- Institute of Physics, University of Silesia, Katowice, Poland
| | - A Knight
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - A Knox
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - L Koch
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - T Koga
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A Konaka
- TRIUMF, Vancouver, British Columbia, Canada
| | - K Kondo
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A Kopylov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L L Kormos
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - A Korzenev
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - Y Koshio
- Department of Physics, Okayama University, Okayama, Japan
| | - W Kropp
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - R Kurjata
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - T Kutter
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - J Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - I Lamont
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - E Larkin
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - P Lasorak
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - M Laveder
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padova, Italy
| | - M Lawe
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - M Lazos
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - T Lindner
- TRIUMF, Vancouver, British Columbia, Canada
| | - Z J Liptak
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - R P Litchfield
- Department of Physics, Imperial College London, London, United Kingdom
| | - X Li
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - A Longhin
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padova, Italy
| | - J P Lopez
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - L Ludovici
- INFN Sezione di Roma and Università di Roma "La Sapienza", Roma, Italy
| | - X Lu
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - L Magaletti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - K Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - M Malek
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - S Manly
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - A D Marino
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - J Marteau
- Université de Lyon, Université Claude Bernard Lyon 1, IPN Lyon (IN2P3), Villeurbanne, France
| | - J F Martin
- Department of Physics, University of Toronto, Toronto, Ontario, Canada
| | - P Martins
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - S Martynenko
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - T Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Mavrokoridis
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - W Y Ma
- Department of Physics, Imperial College London, London, United Kingdom
| | | | - M McCarthy
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - N McCauley
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - K S McFarland
- Department of Physics and Astronomy, University of Rochester, Rochester, New York, USA
| | - C McGrew
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - A Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Metelko
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - M Mezzetto
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padova, Italy
| | - P Mijakowski
- National Centre for Nuclear Research, Warsaw, Poland
| | - A Minamino
- Department of Physics, Kyoto University, Kyoto, Japan
| | - O Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
| | - A Missert
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - M Miura
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - S Moriyama
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - Th A Mueller
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - S Murphy
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - J Myslik
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia, Canada
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - K G Nakamura
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - K D Nakamura
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Nakayama
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - T Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - C Nantais
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - C Nielsen
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - M Nirkko
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Nishimura
- Institute for Cosmic Ray Research, University of Tokyo, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - P Novella
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - J Nowak
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - H M O'Keeffe
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - R Ohta
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, University of Tokyo, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Okusawa
- Department of Physics, Osaka City University, Osaka, Japan
| | - W Oryszczak
- Faculty of Physics, University of Warsaw, Warsaw, Poland
| | - S M Oser
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - T Ovsyannikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - R A Owen
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Palladino
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Napoli, Italy
| | - J L Palomino
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - V Paolone
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - N D Patel
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Pavin
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - D Payne
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - J D Perkin
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - Y Petrov
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - L Pickard
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - L Pickering
- Department of Physics, Imperial College London, London, United Kingdom
| | - E S Pinzon Guerra
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - C Pistillo
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - B Popov
- UPMC, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | | | | | | | - P Przewlocki
- National Centre for Nuclear Research, Warsaw, Poland
| | - B Quilain
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T Radermacher
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - E Radicioni
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - P N Ratoff
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - M Ravonel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - M A M Rayner
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - A Redij
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - E Reinherz-Aronis
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - C Riccio
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Napoli, Italy
| | - P Rojas
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - E Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - S Roth
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - A Rubbia
- ETH Zurich, Institute for Particle Physics, Zurich, Switzerland
| | - A Rychter
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - R Sacco
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - F Sánchez
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona), Spain
| | - F Sato
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - E Scantamburlo
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina, USA
| | - S Schoppmann
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - J Schwehr
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - M Scott
- TRIUMF, Vancouver, British Columbia, Canada
| | - Y Seiya
- Department of Physics, Osaka City University, Osaka, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - H Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - D Sgalaberna
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - R Shah
- Department of Physics, Oxford University, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - A Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Shaker
- Department of Physics, University of Winnipeg, Winnipeg, Manitoba, Canada
| | - D Shaw
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - M Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - T Shirahige
- Department of Physics, Okayama University, Okayama, Japan
| | - S Short
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - M Smy
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
| | - J T Sobczyk
- Faculty of Physics and Astronomy, Wroclaw University, Wroclaw, Poland
| | - H Sobel
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Sorel
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - L Southwell
- Physics Department, Lancaster University, Lancaster, United Kingdom
| | - P Stamoulis
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - J Steinmann
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - T Stewart
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - P Stowell
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - Y Suda
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - S Suvorov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - K Suzuki
- Department of Physics, Kyoto University, Kyoto, Japan
| | - S Y Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - R Tacik
- Department of Physics, University of Regina, Regina, Saskatchewan, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - M Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - S Takahashi
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A Takeda
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - Y Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kobe University, Kobe, Japan
| | - H K Tanaka
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - H A Tanaka
- Department of Physics, University of Toronto, Toronto, Ontario, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - D Terhorst
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - R Terri
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - T Thakore
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - L F Thompson
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - S Tobayama
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - W Toki
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - T Tomura
- Institute for Cosmic Ray Research, University of Tokyo, Kamioka Observatory, Kamioka, Japan
| | - C Touramanis
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tzanov
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Y Uchida
- Department of Physics, Imperial College London, London, United Kingdom
| | - A Vacheret
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - M Vagins
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - Z Vallari
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - G Vasseur
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - T Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - K Wakamatsu
- Department of Physics, Osaka City University, Osaka, Japan
| | - C W Walter
- Department of Physics, Duke University, Durham, North Carolina, USA
| | - D Wark
- Department of Physics, Oxford University, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - W Warzycha
- Faculty of Physics, University of Warsaw, Warsaw, Poland
| | - M O Wascko
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Department of Physics, Imperial College London, London, United Kingdom
| | - A Weber
- Department of Physics, Oxford University, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - R Wendell
- Department of Physics, Kyoto University, Kyoto, Japan
| | - R J Wilkes
- Department of Physics, University of Washington, Seattle, Washington, USA
| | - M J Wilking
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - C Wilkinson
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - J R Wilson
- School of Physics and Astronomy, Queen Mary University of London, London, United Kingdom
| | - R J Wilson
- Department of Physics, Colorado State University, Fort Collins, Colorado, USA
| | - Y Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Yamamoto
- Department of Physics, Osaka City University, Osaka, Japan
| | - M Yamamoto
- Department of Physics, Kyoto University, Kyoto, Japan
| | - C Yanagisawa
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, New York, USA
| | - T Yano
- Kobe University, Kobe, Japan
| | - S Yen
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Yokoyama
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - J Yoo
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA
| | - K Yoshida
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T Yuan
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - M Yu
- Department of Physics and Astronomy, York University, Toronto, Ontario, Canada
| | - A Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - L Zambelli
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Zaremba
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - M Ziembicki
- Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland
| | - E D Zimmerman
- Department of Physics, University of Colorado at Boulder, Boulder, Colorado, USA
| | - M Zito
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - J Żmuda
- Faculty of Physics and Astronomy, Wroclaw University, Wroclaw, Poland
| |
Collapse
|
50
|
Reddy V, Short S, Williams C. Bves Deletion Expands the Intestinal Stem Cell Compartment and Alters Wnt and Notch Signaling in the Small Intestine. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|